Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 10643. Отображено 100.
12-01-2012 дата публикации

Preparation of 2-chloro-9-(2'-deoxy-2'-fluoro-Beta-D-arabinofuranosyl)-adenine

Номер: US20120010397A1
Принадлежит: Scinopharm Taiwan Ltd

A process for making clofarabine comprising: fluorinating a compound of formula VII wherein each R 4 is independently a hydroxy protecting group, OR 6 is a leaving group, with a fluorinating agent in the presence of guanidine carbonate to give a compound of formula VIII: wherein R 4 is as defined above; and deprotecting the compound of formula VIII to give the clofarabine.

Подробнее
01-03-2012 дата публикации

Cyanine dyes

Номер: US20120052506A1
Принадлежит: Pacific Biosciences of California Inc

The invention provides a novel class of cyanine dyes that are functionalized with sulfonic acid groups and a linker moiety that facilitates their conjugation to other species and substituent groups which increase the water-solubility, and optimize the optical properties of the dyes. Also provided are conjugates of the dyes, methods of using the dyes and their conjugates and kits including the dyes and their conjugates.

Подробнее
01-03-2012 дата публикации

Phospholinked dye analogs with an amino acid linker

Номер: US20120052507A1
Автор: Gene Shen
Принадлежит: Pacific Biosciences of California Inc

In various embodiments, the present invention provides fluorescent dyes that are linked to another species through an amino acid or peptide linker. In an exemplary embodiment, the dye is linked to a polyphosphate nucleic acid through an amino acid or peptide linker. These conjugates find use in single molecule DNA sequencing and other applications. In various embodiments, the dye moiety is a cyanine dye. Cyanine dyes that are highly charged, such as those including muliple sulfonate, alkylsulfonate, carboxylate and/or alkylcarboxylate moieties are examples of cyanine dyes of use in the compounds of the invention.

Подробнее
08-03-2012 дата публикации

Phosphonate Compounds

Номер: US20120058975A1
Принадлежит: UNIVERSITY OF CALIFORNIA

The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.

Подробнее
08-03-2012 дата публикации

Methods of using oligomeric compounds comprising 2'-substituted nucleosides

Номер: US20120059045A1
Принадлежит: ISIS PHARMACEUTICALS INC

The present disclosure provides oligomeric compounds comprising at least one 2′-fluoroethoxy modified nucleoside of formula I and methods of using these oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

Подробнее
03-05-2012 дата публикации

Labelling Strategies for the Sensitive Detection of Analytes

Номер: US20120107943A1
Принадлежит: BASECLICK GMBH

The present invention relates to methods and reagents for detecting analytes, e.g. nucleic acids. The new methods and reagents allow a simple and sensitive detection even in complex biological samples.

Подробнее
03-05-2012 дата публикации

Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production

Номер: US20120108531A1
Принадлежит: KU Leuven Research and Development

Disclosed herein are novel phosphonate nucleosides and thiophosphonate nucleosides comprising a phosphonalkoxy-substituted or phosphonothioalkyl-substituted five-membered, saturated or unsaturated, oxygen-containing or sulfur-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base. The invention further relates to compounds having HIV (Human Immunodeficiency Virus) replication inhibiting properties and to compounds having antiviral activities with respect to other viruses. The invention also relates to methods for preparation of all such compounds and pharmaceutical compositions comprising them. The invention further relates to the use of said compounds as a medicine and in the manufacture of a medicament useful for the treatment of subjects suffering from HIV infection, as well as for treatment of other viral, retroviral or lentiviral infections and to the treatment of animals suffering from FIV, viral, retroviral or lentiviral infections.

Подробнее
10-05-2012 дата публикации

Method for the solid phase-based production of phosphate-bridged nucleoside conjugates

Номер: US20120116067A1
Принадлежит: UNIVERSITAET HAMBURG

The invention relates to a method for producing phosphate-bridged nucleoside conjugates. In the method, a cyclosaligenyl nucleotide is produced first, to which a linker is added, which is used to perform the immobilization on a solid phase. A subsequent reaction with corresponding nucleophiles results in the desired phosphate-bridged nucleoside conjugates, which can then again be cleaved from the solid phase-bound linker.

Подробнее
17-05-2012 дата публикации

Lung-targeted drugs

Номер: US20120122818A1
Принадлежит: UNIVERSITY OF CALIFORNIA

Methods and compositions are provided for treating lung diseases, including but not limited to infections and small cell and non-small cell lung cancer, by conjugating a drug of interest to glycerol ethers or glycerol phosphate ethers.

Подробнее
14-06-2012 дата публикации

2'-fluoro arabino nucleosides and use thereof

Номер: US20120149657A1
Принадлежит: Southern Research Institute

A method of treating cancer using certain 2′-fluoro arabino nucleosides is provided. Also provided are compounds represented by the formula: (I & A) wherein R is alkyl; and pharmaceutically acceptable salts thereof; and pharmaceutical compositions containing these compounds.

Подробнее
02-08-2012 дата публикации

Methods for transdifferentiation of body tissues

Номер: US20120196826A1
Автор: Steven Baranowitz
Принадлежит: Individual

The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune disease.

Подробнее
16-08-2012 дата публикации

Bridged artificial nucleoside and nucleotide

Номер: US20120208991A1
Принадлежит: Osaka University NUC

It is an object of the present invention to provide a novel molecule for antisense therapies which is not susceptible to nuclease degradation in vivo and has a high binding affinity and specificity for the target mRNAs and which can efficiently regulate expression of specific genes. The novel artificial nucleoside of the present invention has an amide bond introduced into a bridge structure of 2′,4′-BNA/LNA. The oligonucleotide containing the 2′,4′-bridged artificial nucleotide has a binding affinity for a single-stranded RNA comparable to known 2′,4′-BNA/LNA and has an increased nuclease resistance over LNA. Particularly, it is expected to be applied to nucleic acid drugs because of its much stronger binding affinity for single-stranded RNAs than S-oligo's affinity

Подробнее
30-08-2012 дата публикации

Method for the manufacture of 2-fluoro-ara-adenine

Номер: US20120220762A1
Принадлежит: Alcafleu Management GmbH and Co KG

A method is described for the manufacture of pure 2-fluoro-ara-adenine of Formula (I) from 2-fluoro-ara-adenine triacetate using potassium carbonate (K 2 CO 3 ), wherein the 2-fluoro-ara-adenine has a reduced dimer contents, as well as the compound 2-fluoro-ara-adenine having a dimer contents of ≦0.3%.

Подробнее
04-10-2012 дата публикации

Compounds and pharmaceutical compositions for the treatment of viral infections

Номер: US20120251487A1
Автор: Dominique Surleraux
Принадлежит: IDENIX Pharmaceuticals LLC

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

Подробнее
11-10-2012 дата публикации

Inhibitors of e1 activating enzymes

Номер: US20120258927A1
Принадлежит: Millennium Pharmaceuticals Inc

This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.

Подробнее
13-12-2012 дата публикации

Novel nucleic acid prodrugs and methods of use thereof

Номер: US20120316224A1
Принадлежит: Ontorii Inc

Described herein are nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties. Also described herein are methods of making and using nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties.

Подробнее
13-12-2012 дата публикации

Synthesis of purine nucleosides

Номер: US20120316327A1
Принадлежит: GILEAD PHARMASSET LLC

A process for preparing phosphoramidate prodrugs or cyclic phosphate prodrugs of nucleoside derivatives, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof.

Подробнее
17-01-2013 дата публикации

Methods and compositions for treating hepatitis c virus

Номер: US20130017171A1

A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Подробнее
24-01-2013 дата публикации

Modular nucleotide compositions and uses therefor

Номер: US20130022968A1
Принадлежит: Pacific Biosciences of California Inc

Nucleic acid compositions, methods of making and using such compositions that comprise modular functional groups that can be configured to provide desired functionality to different nucleotide types, through a swappable and preferably non-covalent linkage component. Such compositions are useful in a variety of applications including nucleic acid analyses.

Подробнее
31-01-2013 дата публикации

Nucleoside phosphoramidate prodrugs

Номер: US20130029929A1
Принадлежит: GILEAD PHARMASSET LLC

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

Подробнее
14-02-2013 дата публикации

Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels

Номер: US20130040907A1
Принадлежит: Ardea Biociences Inc

Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

Подробнее
21-02-2013 дата публикации

N6-substituted adenosine derivatives and n6-substituted adenine derivatives and uses thereof

Номер: US20130045942A1
Принадлежит: Institute of Materia Medica of CAMS

The present invention provides N 6 -substituted adenosine derivatives and N 6 -substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

Подробнее
21-03-2013 дата публикации

PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING

Номер: US20130072388A1
Принадлежит:

Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3′-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group. 2. A compound according to claim 1 , wherein the cleavable terminating moiety is attached to the base through a linkage selected from the group consisting of benzyl amine claim 1 , benzyl ether claim 1 , carbamate claim 1 , carbonate claim 1 , 2-(o-nitrophenyl)ethyl carbamate claim 1 , and 2-(o-nitrophenyl)ethyl carbonate.4. A compound according to claim 3 , wherein Rand Rare selected from the group consisting of —CH claim 3 , —CHCH claim 3 , —CHCHCH claim 3 , isopropyl claim 3 , tert-butyl claim 3 , phenyl claim 3 , 2-nitrophenyl claim 3 , and 2 claim 3 ,6-dinitrophenyl.5. A compound according to claim 3 , wherein Rand Rare selected from the group consisting of alkyl and aromatic groups optionally containing at least one heteroatom in the alkyl or aromatic groups claim 3 , and further wherein the aromatic group may optionally be an aryl or polycyclic group.6. A compound according to claim 3 , wherein R claim 3 , R claim 3 , R claim 3 , and Rare selected from an aromatic group consisting of aryl and ...

Подробнее
28-03-2013 дата публикации

2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES

Номер: US20130078217A1
Принадлежит:

The present invention relates to 2′-chloroacetylenyl-substituted nucleoside derivatives of the general formula (I): 9. A pharmaceutical composition comprising an inhibitory amount of a compound according to claim 1 , in combination with a pharmaceutically acceptable carrier or excipient.10. A method of treating a viral infection in a subject claim 9 , comprising administering to the subject an inhibitory amount of a pharmaceutical composition according to .11. The method according to claim 10 , wherein the viral infection is hepatitis C virus.12. A method of inhibiting the replication of hepatitis C virus claim 9 , the method comprising supplying a hepatitis C viral NS3 protease inhibitory amount of the pharmaceutical composition of .13. The method of further comprising administering concurrently an additional anti-hepatitis C virus agent.14. The method of claim 11 , wherein said additional anti-hepatitis C virus agent is selected from the group consisting of α-interferon claim 11 , β-interferon claim 11 , ribavarin claim 11 , and adamantine.15. The method of claim 12 , wherein said additional anti-hepatitis C virus agent is an inhibitor of hepatitis C virus helicase claim 12 , polymerase claim 12 , metalloprotease claim 12 , or IRES.16. The pharmaceutical composition of claim 9 , further comprising another anti-HCV agent.17. The pharmaceutical composition of claim 9 , further comprising an agent selected from interferon claim 9 , ribavirin claim 9 , amantadine claim 9 , another HCV protease inhibitor claim 9 , an HCV polymerase inhibitor claim 9 , an HCV helicase inhibitor claim 9 , or an internal ribosome entry site inhibitor.18. The pharmaceutical composition of claim 9 , further comprising pegylated interferon.19. The pharmaceutical composition of claim 9 , further comprising another anti-viral claim 9 , anti-bacterial claim 9 , anti-fungal or anti-cancer agent claim 9 , or an immune modulator.20. The composition of claim 9 , further comprising a cytochrome P450 ...

Подробнее
04-04-2013 дата публикации

MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Номер: US20130084576A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 158.-. (canceled)60. The compound of wherein Mis O.61. The compound of wherein J claim 60 , J claim 60 , Jand Jare each H.62. The compound of wherein Jforms a bridge with one of Jor J.64. The compound of wherein Qand Qare each H.66. The compound of wherein G is halogen claim 65 , OCH claim 65 , OCHF claim 65 , OCHF claim 65 , OCF claim 65 , OCHCH claim 65 , O(CH)F claim 65 , OCHCHF claim 65 , OCHCF claim 65 , OCH—CH═CH claim 65 , O(CH)—OCH claim 65 , O(CH)—SCH claim 65 , O(CH)—OCF claim 65 , O(CH)—N(R)(R) claim 65 , O(CH)—ONO(R)(R) claim 65 , O(CH)—O(CH)—N(R)(R) claim 65 , OCHC(═O)—N(R)(R) claim 65 , OCHC(═O)—N(R)—(CH)—NR)(R) or O(CH)—N(R)—C(═NR)[N(R)(R)] wherein R claim 65 , R claim 65 , Rand Rare each claim 65 , independently claim 65 , H or C-Calkyl.67. The compound of wherein said heterocyclic base moiety is a pyrimidine claim 66 , substituted pyrimidine claim 66 , purine or substituted purine.68. The compound of wherein said heterocyclic base moiety is uracil claim 67 , thymine claim 67 , cytosine claim 67 , 5-methylcytosine claim 67 , adenine or guanine.70. The oligomeric compound of wherein Mis O.71. The oligomeric compound of wherein J claim 70 , J claim 70 , Jand Jare each H.72. The oligomeric compound of wherein Jforms a bridge with one of Jor J.74. The oligomeric compound of wherein Qand Qare each H.76. The oligomeric compound of wherein Ris O and Rand Rare each claim 75 , independently claim 75 , OCH claim 75 , OCHCHor OCH(CH). ...

Подробнее
04-04-2013 дата публикации

ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT

Номер: US20130085133A1

The present disclosure relates to novel compounds of formulas (1) through (19) and to a method for treating humans infected with a virus including various respiratory viruses such as members of the Paramyxoviridae family (respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human parainfluenza virus (HPIV), measles virus, and mumps virus) with a compound of formulas (1) through (19). The present disclosure also relates to a cytopathic effect (CPE)-based assay that will assess virus-induced CPE for screening of compounds for treating viral diseases or inhibiting a virus. 2. The method of wherein the virus is a respiratory virus.3. The method of wherein the virus is selected from the group consisting of the families Paramyxoviridae claim 1 , human metapneumovirus claim 1 , human parainfluenza virus claim 1 , measles virus claim 1 , and mumps virus.4. The method of wherein the virus is respiratory syncytial virus.6. The method of wherein the virus is a respiratory virus.7. The method of wherein the virus is selected from the group consisting of the families Paramyxoviridae claim 5 , human metapneumovirus claim 5 , human parainfluenza virus claim 5 , measles virus claim 5 , and mumps virus.8. The method of wherein the virus is respiratory syncytial virus.9. A method for screening for compounds for use as an anti-viral agent against a virus which comprises obtaining frozen cells infected with said virus claim 5 , thawing said infected cells and mixing said infected cells with uninfected cells of the same type as the infected cells claim 5 , contacting the mixture of said infected cells and uninfected cells with a compound to be screened and determining the viability of said cells.10. The method of wherein the virus is a respiratory virus.11. The method of wherein the virus is selected from the group consisting of the families Paramyxoviridae claim 9 , human metapneumovirus claim 9 , human parainfluenza virus claim 9 , measles virus claim 9 , and mumps virus. ...

Подробнее
11-04-2013 дата публикации

Phosphonate analogs of hiv inhibitor compounds

Номер: US20130090299A1
Принадлежит: Gilead Sciences Inc

The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Подробнее
11-04-2013 дата публикации

CRYSTALLIZATION PROCESS OF CYCLIC ADENOSINE 3',5'-MONOPHOSPHATE

Номер: US20130090466A1
Принадлежит:

Provided is a crystallization process of cyclic adenosine 3′,5′-monophosphate, which comprises the following steps: 1) reacting an aqueous solution of cyclic adenosine 3′,5′-monophosphate with a base to obtain a salt of cyclic adenosine 3′,5′-monophosphate; 2) reacting the cyclic adenosine 3′,5′-monophosphate salt solution obtained in step 1) with an acid to obtain cyclic adenosine 3′,5′-monophosphate; 3) keeping cyclic adenosine 3′,5′-monophosphate obtained in step 2) at 0-15° C. 110-. (canceled)11. A crystallization method of 3′ ,5′-cyclic adenosine monophosphate , wherein said method comprises the following steps:1) reacting 3′,5′-cyclic adenosine monophosphate aqueous solution with a base to produce 3′,5′-cyclic adenosine monophosphate salt solution;2) reacting the 3′,5′-cyclic adenosine monophosphate salt solution produced in step 1) with an acid to produce 3′,5′-cyclic adenosine monophosphate; and3) preserving the 3′,5′-cyclic adenosine monophosphate produced in step 2) at 0-15° C.12. The method according to claim 11 , wherein in said step 1) claim 11 , 3′ claim 11 ,5′-cyclic adenosine monophosphate aqueous solution is reacted with a base until the pH value of the solution reaches pH 6.0-10.0.13. The method according to claim 12 , wherein said base is one or more selected from ammonia water and sodium hydroxide claim 12 , the concentration of which is 2-10 M.14. The method according to claim 12 , wherein the concentration of said 3′ claim 12 ,5′-cyclic adenosine monophosphate aqueous solution is 15-350 g/L.15. The method according to claim 11 , wherein in said step 2) claim 11 , 3′ claim 11 ,5′-cyclic adenosine monophosphate salt solution is reacted with an acid until the pH value of the solution reaches pH 1.0-5.0.16. The method according to claim 15 , wherein said acid is one or more selected from sulfuric acid claim 15 , hydrochloric acid and phosphoric acid claim 15 , the concentration of which is 0.01-10 M.17. The method according to claim 11 , wherein ...

Подробнее
18-04-2013 дата публикации

New Method of Using N-Thio Compounds for Oligonucleotide Synthesis

Номер: US20130096291A1
Принадлежит: GIRINDUS AMERICA, INC.

A method for synthesizing an oligonucleotide which comprises using a sulfurizing agent of general formula (I) for sulfurizing at least one phosphorus internucleotide linkage of a precursor of the oligonucleotide, wherein R is an aryl group or a heteroaryl group, which is bonded to the S-atom through an annular carbon atom; and Rand Rare independently organic residues, preferably a C1-C20 hydrocarbon residue. The method may further comprise purifying the oligonucleotide. Also included is a process for the synthesis of the sulfurizing agent. 2. The method according to claim 1 , wherein R is a halophenyl or alkylphenyl claim 1 , Preferably 4-halophenyl claim 1 , especially preferably 4-chlorophenyl.3. The method according to any one of and wherein Rand Rare selected from lower alkyl or cycloalkyl (C1-C7) claim 1 , phenyl including substituted phenyl and naphthyl groups claim 1 , more preferably a methyl group.4. The method according to any one of to claim 1 , wherein the sulfurizing agent is dissolved in an organic solvent preferably a halogenated hydrocarbon solvent.5. The method according to any one of to claim 1 , wherein the molar ratio of sulfurizing agent to phosphorus internucleotide linkages to be sulfurized is from 1.0 to 2.0.6. The method according to any one of to claim 1 , wherein the precursor of said oligonucleotide contains nucleosides selected from ribonucleosides claim 1 , 2′-deoxyribonucleosides claim 1 , 2′-substituted ribonucleosides claim 1 , 2′-4′-locked-ribonucleosides claim 1 , 3′-amino-ribonucleosides claim 1 , 3′-amino-2′-deoxyribonucleosides.7. The method according to any one of to claim 1 , wherein the phosphorus internucleotide linkage is an H-phosphonate diester bond.8. The method according to claim 7 , wherein the coupling is carried out in solution phase.9. The method according to anyone of to which further comprises a step of purifying the oligonucleotide obtained according to anyone of to .10. The method according to which comprises at ...

Подробнее
25-04-2013 дата публикации

MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF

Номер: US20130102034A1
Автор: Schrum Jason P.
Принадлежит:

The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using thereof. 1. A compound comprising a nucleotide that disrupts binding of a major groove binding partner with a nucleic acid comprising the nucleotide , wherein the nucleotide has decreased binding affinity to the major groove binding partner.2. The compound of claim 1 , wherein the nucleotide comprises a chemical modification located on the major groove face of a nucleobase portion of the nucleotide.3. The compound of claim 2 , wherein the nucleobase portion comprises a pyrimidine nucleobase claim 2 , and wherein the chemical modification comprises replacing or substituting an atom of the major groove face of the pyrimidine nucleobase with an amine claim 2 , an SH claim 2 , a methyl claim 2 , an ethyl claim 2 , a chloro or a fluoro group.4. The compound of claim 2 , wherein the chemical modification is located on a sugar portion of the nucleotide.5. The compound of claim 2 , wherein the chemical modification is located on a phosphate backbone of the nucleotide.9. The compound of claim 6 , wherein B is a nucleobase selected from the group consisting of cytosine claim 6 , guanine claim 6 , adenine claim 6 , and uracil.15. A nucleic acid sequence comprising at least two nucleotides claim 6 , the nucleic acid sequence comprising a nucleotide that disrupts binding of a major groove binding partner with the nucleic acid sequence claim 6 , wherein the nucleotide has decreased binding affinity to the major groove binding partner.19. The nucleic acid sequence of claim 16 , wherein B is a nucleobase selected from the group consisting of cytosine claim 16 , guanine claim 16 , adenine claim 16 , and uracil.20. The nucleic acid sequence of claim 16 , wherein the nucleic acid sequence contains a plurality of structurally unique compounds of Formula I-d.21. The nucleic acid sequence of claim 16 , wherein at least 25% of the cytosines are replaced by a compound of Formula I-d ...

Подробнее
02-05-2013 дата публикации

Method of ameliorating oxidative stress and supplementing the diet

Номер: US20130108605A1

A method of supplementing a diet and ameliorating oxidative stress in a mammal includes administering a pharmaceutically effective amount of lipid soluble, hydrophobic active compounds having a chemical structure: wherein R 1 is an aromatic backbone and R 2 is a sulfur containing ligand. Through formation of disulfide linkages other moieties can be attached to R 2 converting the hydrophobic base into a water soluble entity, for ease of delivery, which can be reconverted back to the original compound by biochemical reduction in the blood stream.

Подробнее
02-05-2013 дата публикации

Detection or quantification of desirable target molecules, novel dyes, composite dyes, and oligonucleotides or polynucleotides comprising such dyes

Номер: US20130109847A1

The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins and nucleic acids. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes are also provided that comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been modified by the addition of charged and polar groups to provide beneficial properties. 2. The dye of claim 1 , wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , or Rfurther comprises a reactive group.3. The dye of claim 2 , wherein said reactive group comprises a nucleophilic reactive group claim 2 , an electrophilic reactive group claim 2 , a terminal alkene claim 2 , a terminal alkyne claim 2 , a coordinate group or an alkylating agent.4. The dye of claim 3 , wherein said nucleophilic reactive group comprises a thiol claim 3 , amine or hydroxyl group.5. The dye of claim 3 , wherein said electrophilic reactive group comprises an isocyanate claim 3 , isothiocyanate claim 3 , monochlorotriazine claim 3 , dichlorotriazine claim 3 , 4 claim 3 ,6 claim 3 ,-dichloro-1 claim 3 ,3 claim 3 ,5-triazines claim 3 , mono- or di-halogen substituted pyridine claim 3 , mono- or di-halogen substituted diazine claim 3 , maleimide claim 3 , haloacetamide claim 3 , aziridine claim 3 , sulfonyl halide claim 3 , acid halide claim 3 , hydroxysuccinimide ester claim 3 , hydroxysulfosuccinimide ester claim 3 , imido ester claim 3 , hydrazine claim 3 , azidonitrophenol claim 3 , azide claim 3 , 3-(2-pyridyl dithio)-proprionamide claim 3 , glyoxal or aldehyde group.6. The dye of claim 1 , wherein said dye further comprises one or more charged groups or polar groups.7. ...

Подробнее
02-05-2013 дата публикации

MODIFIED 5' DIPHOSPHATE NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Номер: US20130109850A1
Принадлежит: Isis Pharmaceuticals, Inc

Provided herein are modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom. More particularly, modified 5′ diphosphate nucleosides are provided that can be further modified at the 2′ and 5′ positions. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The oligomeric compounds are also expected to be useful as primers and probes in diagnostic applications. 150-. (canceled)52. The compound of wherein Bx is uracil claim 51 , thymine claim 51 , cytosine claim 51 , 5-methylcytosine claim 51 , adenine or guanine.53. The compound of any one of wherein r is 1 claims 52 , Mis H and Mis OH.54. The compound of any one of wherein r is 0 claims 53 , Mis O(CH)CN and Mis N[CH(CH)].55. The compound of wherein G is halogen claim 54 , OCH claim 54 , OCHF claim 54 , OCHF claim 54 , OCF claim 54 , OCHCH claim 54 , O(CH)F claim 54 , OCHCHF claim 54 , OCHCF claim 54 , OCH—CH═CH claim 54 , O(CH)—OCH claim 54 , O(CH)—SCH claim 54 , O(CH)—OCF claim 54 , O(CH)—N(R)(R) claim 54 , O(CH)—ON(R)(R) claim 54 , O(CH)—O(CH)—N(R)(R) claim 54 , OCHC(═O)—N(R)(R) claim 54 , OCHC(═O)—N(R)—(CH)—N(R)(R) or O(CH)—N(R)—C(═NR)[N(R)(R)] wherein R claim 54 , R claim 54 , Rand Rare each claim 54 , independently claim 54 , H or C-Calkyl.56. The compound of wherein G is halogen claim 55 , OCH claim 55 , OCF claim 55 , OCHCH claim 55 , OCHCF claim 55 , OCH—CH═CH claim 55 , O(CH)—OCH claim 55 , O(CH)—O(CH)—N(CH) claim 55 , OCHC(═O)—N(H)CH claim 55 , OCHC(═O)—N(H)—(CH)—N(CH)or OCH—N(H)—C(═NH)NH.57. The compound of wherein G is F claim 56 , OCH claim 56 , O(CH)—OCH claim 56 , OCHC(═O)—N(H)CHor OCHC(═O)—N(H)—(CH)—N(CH).58. The compound of wherein G is O(CH)—OCH.59. The compound of wherein each Pg is claim 58 , independently claim 58 , methyl claim 58 , ethyl claim 58 , isopropyl claim 58 , tert-butyl claim 58 , 2-cyanoethyl claim 58 , benzyl claim 58 , phenyl claim 58 , 4- ...

Подробнее
09-05-2013 дата публикации

5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM

Номер: US20130116420A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present invention provides 5′ modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5′-substituent and an optional 2′ substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 146-. (canceled)48. The 5′ modified nucleoside of wherein Bx is uracil claim 47 , thymine claim 47 , cytosine claim 47 , 5-methylcytosine claim 47 , adenine or guanine.49. The 5′ modified nucleoside of wherein qand qare each claim 48 , independently claim 48 , OCH claim 48 , OCHCHor OC(H)(CH)and qis O.50. The 5′ modified nucleoside of wherein r is 1 claim 49 , Mis H and Mis hydroxyl or r is 0 claim 49 , Mis O(CH)CN and Mis N[CH(CH)].51. The 5′ modified nucleoside of wherein G is halogen claim 50 , OCH claim 50 , OCHF claim 50 , OCHF claim 50 , OCF claim 50 , OCHCH claim 50 , O(CH)F claim 50 , OCHCHF claim 50 , OCHCF claim 50 , OCH—CH═CH claim 50 , O(CH)—OCH claim 50 , O(CH)—SCH claim 50 , O(CH)—OCF claim 50 , O(CH)—N(R)(R) claim 50 , O(CH)—ON(R)(R) claim 50 , O(CH)—O(CH)—N(R)(R) claim 50 , OCHC(═O)—N(R)(R) claim 50 , OCHC(═O)—N(R)—(CH)—N(R)(R) or O(CH)—N(R)—C(═NR)[N(R)(R)] wherein R claim 50 , R claim 50 , Rand Rare each claim 50 , independently claim 50 , H or C-Calkyl.52. The 5′ modified nucleoside of wherein G is F claim 51 , OCH claim 51 , O(CH)—OCH claim 51 , OCHC(═O)—N(H)CHor OCHC(═O)—N(H)—(CH)—N(CH).53. The 5′ modified nucleoside of wherein g is 1.54. The 5′ modified nucleoside of wherein three of q claim 53 , q claim 53 , qand qare each H.55. The 5′ modified nucleoside of wherein one of qand qis H claim 53 , one of qand qis H and the other two of q claim 53 , q claim 53 , qand qare other than H.56. The 5′ modified nucleoside of wherein ...

Подробнее
16-05-2013 дата публикации

3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING

Номер: US20130122489A1
Принадлежит:

The present invention relates generally to 3′-OH unblocked nucleotides and nucleosides labeled and unlabeled with 5-methoxy-substituted nitrobenzyl-based photocleavable terminating groups for use in methods and systems related to DNA and RNA sequencing and analysis. These compounds may be used as reversible terminators as they exhibit fast nucleotide incorporation kinetics, single-base termination, high nucleotide selectivity, and rapid terminating group cleavage that results in a naturally occurring nucleotide. 2. The compound of claim 1 , further defined as a compound of formula I.3. The compound of claim 1 , further defined as a compound of formula II.4. The compound of claim 1 , further defined as a compound of formula III.5. The compound of claim 1 , further defined as a compound of formula IV.6. The compound of claim 1 , further defined as a compound of formula V.7. The compound of claim 1 , further defined as a compound of formula VI.8. The compound of claim 1 , further defined as a compound of formula VII.9. The compound of claim 1 , wherein Ris hydroxy.1011-. (canceled)12. The compound of claim 1 , wherein Ris a triphosphate.13. The compound of claim 1 , wherein Ris an α-thiotriphosphate.14. (canceled)15. The compound of claim 1 , wherein Ris hydrogen.16. The compound of claim 1 , wherein Ris hydroxy.17. The compound claim 1 , wherein Ris alkyl.18. (canceled)19. The compound of claim 1 , wherein Ris isopropyl.20. The compound of claim 1 , wherein Ris tert-butyl.21. The compound of claim 1 , wherein Ris hydrogen.22. The compound of claim 1 , wherein Ris nitro.23. The compound of claim 1 , wherein Ris hydrogen.24. The compound of claim 1 , wherein Ris iodo.25. The compound of claim 1 , wherein Ris alkoxy.26. The compound of claim 25 , wherein Ris methoxy.2736-. (canceled)37. The compound of claim 1 , wherein Ris a -linker-reporter.39. The compound of claim 38 , wherein X is alkynediyl.40. The compound of claim 39 , wherein X is —C≡C—.41. The compound of claim ...

Подробнее
23-05-2013 дата публикации

AGENT FOR ENHANCING THE EFFECT OF SKIN-WHITENING INGREDIENTS AND USES THEREOF

Номер: US20130129651A1
Принадлежит: HAYASHIBARA CO., LTD.

The present invention has objects to provide an agent for enhancing the effect of skin-whitening ingredients which enhances the skin-whitening action of skin-whitening ingredients and has an improved safeness, and to provide a skin-whitening agent, which contains the above agent and a skin-whitening ingredient(s) and has an improved and enhanced skin-whitening action. The present invention solves the above objects by providing an agent for enhancing the effect of skin-whitening ingredients, which contains one or more members selected from the group consisting of guanine and derivatives thereof as an effective ingredient(s); and a skin-whitening agent which contains the above agent along with a skin-whitening ingredient(s) particularly, members derivatives thereof and/or equol including derivatives thereof. 1. An agent for enhancing the effect of skin-whitening ingredients , which comprises one or more members selected from the group consisting of guanine including derivatives thereof as an effective ingredient(s).2. The agent of claim 1 , wherein said guanine including derivatives thereof is one or more members selected from the group consisting of guanine claim 1 , guanosine claim 1 , guanosine monophosphate claim 1 , guanosine diphosphate claim 1 , guanosine triphosphate claim 1 , and glucosylguanosine.3. The agent of claim 1 , which enhances the skin-whitening action of adenine including derivatives thereof and/or equol including derivatives thereof.4. The agent of claim 3 , wherein said adenine including derivatives thereof is one or more members selected from the group consisting of adenine claim 3 , adenosine claim 3 , adenosine monophosphate claim 3 , adenosine diphosphate claim 3 , adenosine triphosphate claim 3 , and glucosyladenosine.5. The agent of claim 3 , wherein said equol including derivatives thereof is equol and/or glycosylequol.6. A skin-whitening agent claim 1 , which comprises the agent of and adenine including derivatives thereof claim 1 , ...

Подробнее
23-05-2013 дата публикации

Lipophilic monophosphorylated derivatives and nanoparticles

Номер: US20130131008A1
Принадлежит: University of Texas System

There are provided, inter alia, lipophilic monophosphorylated derivatives of gemcitabine. There are further provided nanoparticles compositions incorporating lipophilic monophosphorylated derivatives of gemcitabine, pharmaceutical compositions thereof, and a method of treating cancer or a viral infection in a subject in need thereof, which method includes administration of a pharmaceutical composition disclosed herein.

Подробнее
30-05-2013 дата публикации

Crystal Forms of 2--Adenosine

Номер: US20130136693A1

The present invention provides novel crystalline polymorphic forms of 2-cyclohexylmethylidenehydrazino adenosine, also known as binodenoson, methods of making the same, and methods for the manufacture of a pharmaceutical composition by employing such crystal forms, in particular, for the use of binodenoson in a subject, in need thereof, as a pharmacological stress agent to produce coronary vasodilation. 1. A crystal form of 2-{2-[(cyclohexyl)methylene]hydrazino}adenosine (binodenoson) which crystal form is substantially free of other polymorphic forms of binodenoson and has at least one of the following properties:(a) an endotherm by differential scanning calorimetry with an extrapolated onset melting temperature in the range of about 139° C. to about 146° C. when heated at 10° C./min;(b) a X-ray diffraction pattern with characteristic X-ray diffraction peaks at diffraction angles (2θ) of about 5.7±0.2, 10.2±0.2, 14.6±0.2, 19.9±0.2, 21.1±0.2 and 24.6±0.2;(c) an infrared reflectance spectrum with reflectance bands at about 1668±2 and 1592±2; and{'sup': '−1', '(d) a Raman spectrum with Raman shifts at about 1618±2 and 1593±2 cm.'}3. A crystal form according to claim 1 , which crystal form has all four of the properties (a) claim 1 , (b) claim 1 , (c) and (d).4. A crystal form of binodenoson which crystal form is substantially free of other polymorphic forms of binodenoson and has at least one of the following properties:(a) an endotherm by differential scanning calorimetry with an extrapolated onset melting temperature in the range of about 149° C. to about 154° C. when heated at 10° C./min;(b) a X-ray diffraction pattern with characteristic X-ray diffraction peaks at diffraction angles (2θ) of about 5.5±0.2, 10.4±0.2, 16.8±0.2, 20.2±0.2 and 26.0±0.2;{'sup': '−1', '(c) an infrared reflectance spectrum with reflectance bands at about 1646±2 and 1598±2 cm; and'}{'sup': '−1', '(d) a Raman spectrum with Raman shifts at about 1622±2 and 1588±2 cm.'}6. A crystal form ...

Подробнее
30-05-2013 дата публикации

NUCLEOSIDE PHOSPHORAMIDATES

Номер: US20130137654A1
Принадлежит: GILEAD PHARMASSET LLC

Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. 181.-. (canceled)83. The compound according to claim 82 , wherein the compound is at least 98% of the Sstereoisomer represented by the formula (S-4) and not more than 2% of the Rstereoisomer represented by the formula (R-4).84. The compound according to claim 82 , wherein the compound is at least 99% of the Sstereoisomer represented by the formula (S-4) and not more than 1% of the Rstereoisomer represented by the formula (R-4).85. A pharmaceutical composition comprising the compound according to and a pharmaceutically acceptable medium.86. A pharmaceutical composition comprising the compound according to and a pharmaceutically acceptable medium.87. A pharmaceutical composition comprising the compound according to and a pharmaceutically acceptable medium.88. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to .89. The method according to further comprising administering to the human another antiviral agent.90. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to .91. The method according to further comprising administering to the human another antiviral agent.92. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to .93. The method according to further comprising administering to the human another antiviral agent. The right of priority is claimed to U.S. Provisional Patent Application Nos. 61/179,923, filed May 20, 2009, and 61/319,513, filed Mar. 31, 2010, the subject matter ...

Подробнее
06-06-2013 дата публикации

HCV Polymerase Inhibitors

Номер: US20130143835A1
Принадлежит: Medivir AB

The invention provides compounds of the formula: 2. The compound according to claim 1 , wherein Ris H.3. The compound according to claim 1 , wherein Ris C-Calkyl claim 1 , C-Ccycloalkyl or benzyl.4. The compound according to claim 1 , wherein Ris C-Calkyl.5. The compound according to claim 1 , wherein Ris H claim 1 , and R′ is H or C-Calkyl.6. The compound according to claim 1 , wherein one of Rand R′ is H and the other is methyl.7. The compound according to claim 1 , wherein Ris H claim 1 , R′ is C-Calkyl and Ris C-Calkyl or C-Ccycloalkyl.8. The compound according to claim 5 , wherein the configuration at the asymmetric carbon atom to which Rand R′ are attached is that of an L-amino acid.9. A compound according to claim 1 , for use as a medicament.10. The compound according to claim 1 , for use in the treatment or prophylaxis of hepatitis C virus infection.11. A pharmaceutical composition comprising a compound according to in association with a pharmaceutically acceptable adjuvant claim 1 , diluent or carrier.12. A pharmaceutical composition comprising a compound according to claim 1 , further comprising one or more additional other antiviral agent(s).13. A method for the treatment or prophylaxis of hepatitis C virus infection comprising the administration of a compound according to .14. The use of a compound according to in the manufacture of a medicament for the treatment or prophylaxis of hepatitis C virus infection. The present invention relates to inhibitors of the polymerase of hepatitis C virus (HCV), prodrugs thereof and their use in the treatment or prophylaxis of HCV infection.HCV is a single stranded, positive-sense RNA virus belonging to the Flaviviridae family of viruses in the hepacivirus genus. The NS5B region of the RNA polygene encodes an RNA dependent RNA polymerase (RdRp), which is essential to viral replication. Following the initial acute infection, a majority of infected individuals develop chronic hepatitis because HCV replicates ...

Подробнее
06-06-2013 дата публикации

PROCESS FOR THE SYNTHESIS OF CARBONUCLEOSIDE AND INTERMEDIATES FOR USE THEREIN

Номер: US20130144058A1
Принадлежит: Alphora Research Inc.

Disclosed is a process for preparing a carbonucleoside of formula (1) and intermediates for use therein. The process involves the step of reacting a compound of formula (2) with a compound of formula (3) under Mitsunobu-type reaction conditions to obtain a compound of formula (4), wherein PG, PG, PGand PGare protecting groups. The compound of formula (4) is deprotected to form the compound of formula (1), as shown below. 2. The process according to claim 1 , wherein the Mitsunobu type reaction condition comprises an alkyl phosphine or an aryl phosphine claim 1 , and an azo-based compound.3. The process according to claim 2 , wherein the alkyl phosphine is PMe.4. The process according to claim 2 , wherein the aryl phosphine is PPh.5. The process according to claim 2 , wherein the azo based compound is selected from the group consisting of diethylazodicarboxylate (DEAD) claim 2 , diisopropylazodicarboxylate (DIAD) claim 2 , di-t-butylazodicarboxylate claim 2 , 2-(phenylazo)pyridine (azpy) claim 2 , di-p-chlorobenzylazodicarboxylate (DCAD) or 1 claim 2 ,1′-(azodicarboxyl)dipiperidine (ADDP).6. The process according to claim 2 , wherein the azo based compound is diisopropylazodicarboxylate (DIAD).7. The process according to claim 1 , wherein the Mitsunobu type reaction condition comprises a phosphorane ylide.8. The process according to claim 7 , wherein the phosphorane ylide is selected from the group consisting of (cyanomethylene)trimethyl phosphorane or tributylphosphorane.9. The process according to claim 1 , wherein solvent for the Mitsunobu type reaction is selected from the group consisting of tetrahydrofuran claim 1 , acetonitrile claim 1 , dichloromethane claim 1 , toluene claim 1 , or a mixture thereof.10. The process according to claim 1 , wherein solvent for the Mitsunobu type reaction is tetrahydrofuran.11. The process according to claim 1 , wherein the Mitsunobu type reaction is carried out at room temperature.12. The process according to claim 1 , wherein ...

Подробнее
13-06-2013 дата публикации

METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS

Номер: US20130149283A1
Принадлежит:

A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. 2. The method of claim 1 , wherein Rand Rare each independently H; phosphate; a stabilized phosphate prodrug; acyl; or a pharmaceutically acceptable leaving group which claim 1 , when administered in vivo claim 1 , provides a compound wherein Rand Rare each independently H or phosphate.3. The method of claim 1 , wherein Ris hydrogen claim 1 , acyl claim 1 , or phosphate.4. The method of claim 1 , wherein Ris hydrogen or phosphate.5. The method of claim 1 , wherein Ris phosphate.6. The method of claim 1 , wherein Ris hydrogen or acyl.7. The method of claim 1 , wherein Ris hydrogen.8. The method of claim 1 , wherein Ris alkyl.9. The method of claim 1 , wherein Ris methyl.10. The method of claim 1 , wherein Rand Rare each independently hydrogen claim 1 , OR claim 1 , hydroxy claim 1 , alkyl claim 1 , azido claim 1 , cyano claim 1 , alkenyl claim 1 , alkynyl claim 1 , Br-vinyl claim 1 , —C(O)O(alkyl) claim 1 , —C(O)O(lower alkyl) claim 1 , —O(acyl) claim 1 , —O(lower acyl) claim 1 , —O(alkyl) claim 1 , —O(lower alkyl) claim 1 , —O(alkenyl) claim 1 , chloro claim 1 , bromo claim 1 , iodo claim 1 , NO claim 1 , NH claim 1 , —NH(lower alkyl) claim 1 , —NH(acyl) claim 1 , —N(lower alkyl) claim 1 , or —N(acyl).11. The method of claim 1 , wherein Rand Rare each independently hydrogen claim 1 , OR claim 1 , alkyl claim 1 , azido claim 1 , cyano claim 1 , alkenyl claim 1 , alkynyl claim 1 , Br-vinyl claim 1 , —O(alkenyl) claim 1 , chloro claim 1 , bromo claim 1 , iodo claim 1 , NO claim 1 , NH claim 1 , —NH(lower alkyl) claim 1 , —NH(acyl) claim 1 , —N(lower alkyl) claim 1 , or —N(acyl).12. The method of claim 1 , wherein Rand Rare each independently hydrogen claim 1 , OR claim 1 , hydroxy claim 1 , azido claim 1 , cyano ...

Подробнее
13-06-2013 дата публикации

Bicyclic nucleosides and oligomeric compounds prepared therefrom

Номер: US20130150569A1
Принадлежит: ISIS PHARMACEUTICALS INC

The present invention provides novel 3′,5′-linked bicyclic nucleosides and oligomeric compounds prepared therefrom. The bicyclic nucleosides provided herein are useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as nuclease resistance.

Подробнее
20-06-2013 дата публикации

Novel Synthesis of Nucleoside 5'-Triphosphates and Their Derivatives

Номер: US20130158249A1
Автор: Zhen Huang
Принадлежит: Sena Res Inc

Disclosed are compounds of nucleoside 5′-triphosphates of formula (I), or derivatives thereof, or pharmaceutically acceptable salts of said nucleoside 5′-triphosphates or said derivatives, wherein the Base of formula (I) is Adenine (A), Cytosine (C), Guanine (G), Thymine (T), Uracil (U), modified nucleobase or unnatural nucleobase; R 1 is H or OH, R 2 is H or OH, X is independently selected from the group consisting of O, S and Se; and Y is independently selected from the group consisting of O, B (borano, or BH 3 ), S, and Se. Also disclosed are processes of preparing the compounds of formula (I), said process comprising steps according to Scheme A:

Подробнее
27-06-2013 дата публикации

Substituted nucleotide analogs

Номер: US20130164261A1
Принадлежит: Alios Biopharma Inc

Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.

Подробнее
27-06-2013 дата публикации

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Номер: US20130165400A1
Принадлежит: ALIOS BIOPHARMA, INC.

Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. 3. The compound of claim 1 , wherein Ris an optionally substituted acyl.4. The compound of claim 1 , wherein Ris H.5. The compound of claim 1 , wherein Ris an optionally substituted O-linked amino acid.7. The compound of claim 6 , wherein both Rand Rare independently selected from the group consisting of an optionally substituted Calkyl claim 6 , an optionally substituted Calkenyl claim 6 , an optionally substituted Calkynyl claim 6 , an optionally substituted Ccycloalkyl claim 6 , an optionally substituted Ccycloalkenyl claim 6 , an optionally substituted aryl claim 6 , an optionally substituted heteroaryl and an optionally substituted aryl(Calkyl).10. The compound of claim 6 , wherein Ris selected from the group consisting of absent claim 6 , hydrogen claim 6 , an optionally substituted Calkyl claim 6 , an optionally substituted Calkenyl claim 6 , an optionally substituted Calkynyl claim 6 , an optionally substituted Ccycloalkyl and an optionally substituted Ccycloalkenyl; and Ris independently selected from the group consisting of an optionally substituted Calkyl claim 6 , an optionally substituted Calkenyl claim 6 , an optionally substituted Calkynyl claim 6 , an optionally substituted Ccycloalkyl claim 6 , an optionally substituted Ccycloalkenyl and NRR.11. The compound of claim 6 , wherein Ris an optionally substituted aryl; and Ris an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.12. The compound of claim 6 , wherein Rand Rare both an optionally substituted N-linked amino acid ...

Подробнее
27-06-2013 дата публикации

Nucleoside phosphoramidates

Номер: US20130165401A1
Принадлежит: GILEAD PHARMASSET LLC

Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.

Подробнее
27-06-2013 дата публикации

NUCLEOSIDE PHOSPHORAMIDATES

Номер: US20130165644A1
Принадлежит: GILEAD PHARMASSET LLC

Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. 181.-. (canceled)83. The compound according to claim 82 , wherein LG′ is p-nitrophenoxide claim 82 , p-chlorophenoxide claim 82 , o-chlorophenoxide claim 82 , 2 claim 82 ,4-dinitrophenoxide claim 82 , or pentafluorophenoxide.84. The compound according to claim 82 , wherein LG′ is p-nitrophenoxide.85. The compound according to claim 82 , wherein LG′ is p-chlorophenoxide.86. The compound according to claim 82 , wherein LG′ is o-chlorophenoxide.87. The compound according to claim 82 , wherein LG′ is pentafluorophenoxide.88. A process for preparing the compound according to claim 82 , which comprises:{'sub': '2', 'sup': i', 'i, 'reacting (LG′)P(O)(LG), wherein LG and LG′ are independently leaving groups, with isopropyl-alanate and a first base to obtain (LG′)P(O)(LG)(NHAla-Pr), followed by reacting (LG′)P(O)(LG)(NHAla-Pr) with phenol and a second base.'}89. A process for preparing the compound according to claim 82 , which comprises:{'sub': '2', 'reacting (LG′)P(O)(LG), wherein LG and LG′ are independently leaving groups, with phenol and a first base to obtain (LG′)P(O)(LG)(OPh), followed by reacting (LG′)P(O)(LG)(OPh) with isopropyl-alanate and a second base.'}90. A process for preparing the compound according to claim 82 , which comprises:{'sub': '2', 'reacting (LG′)P(O)(LG), wherein LG and LG′ are independently leaving groups, with a combination of isopropyl-alanate, phenol, and at least one base.'}91. A process for preparing the compound according to claim 82 , which comprises:{'sub': '2', 'sup': i', 'i, 'reacting (PhO)P(O)(LG), wherein LG and LG′ are independently leaving groups, with isopropyl-alanate and a first base to obtain (PhO)P(O)(LG)(NHAla-Pr), ...

Подробнее
04-07-2013 дата публикации

LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS

Номер: US20130172285A1
Принадлежит:

The disclosure provides linked purine pterin compounds and analogues thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula I 5. A compound or salt thereof of claim 2 , wherein{'sub': 1', '3', '2, 'Ais oxo and each Ais independently chosen from hydrogen and methyl; and Ris —NH—.'}6. A compound or salt thereof of any one of claim 5 , wherein{'sub': '1', 'Ris methylene optionally substituted with —(C═O)—.'}7. (canceled)8. A compound or salt thereof of claim 2 , wherein{'sub': 1', '1', '1', '4', '1', '4', '1', '2', '1', '2, 'Lis an alkylene linker having from 2 to 4 carbon atoms, wherein Lis unsubstituted or substituted with 1 or more substituents independently chosen from hydroxyl, halogen, amino, C-Calkyl, C-Calkoxy, C-Chaloalkyl, and C-Chaloalkoxy; and'}{'sub': 2', '2', '1', '4', '1', '4', '1', '2', '1', '2', '1', '2, 'Lis an alkylene linker having from 1 to 2 carbon atoms, containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein Lis unsubstituted or substituted with 1 or more substituents independently chosen from hydroxyl, halogen, amino, C-Calkyl, C-Calkoxy, C-Chaloalkyl, and C-Chaloalkoxy; wherein the total number of carbon atoms in the Land Lalkylene linkers is from 3 to 5'}9. (canceled)10. A compound or salt thereof of claim 8 , wherein{'sub': 1', '1, 'Lis an alkylene linker having from 2 to 3 carbon atoms, wherein Lis unsubstituted or substituted with 1 or more substituents independently chosen from halogen and methyl;'}{'sub': 2', '2', '2, 'Lis an alkylene linker of the formula —SCH—, wherein Lis unsubstituted or substituted with 1 or more substituents independently chosen from halogen and methyl; and'}{'sub': 3', '3', '1', '2', '1', '2, 'Ris a piperidinyl, piperazinyl, or pyrrolidinyl ring; each of which Ris unsubstituted or substituted with 1 or more substituents independently chosen from hydroxyl, halogen, C-Calkyl, and C-Calkoxy.'} ...

Подробнее
04-07-2013 дата публикации

METHOD FOR OXIDIZING ALCOHOLS

Номер: US20130172543A1
Принадлежит: TOHOKU UNIVERSITY

A method for oxidizing an alcohol, wherein oxidation is performed in the presence of a compound represented by the following formula (I) and a bulk oxidant, which enables efficient oxidation of secondary alcohols as well as primary alcohols, and can attain high reaction efficiency even when air is used as a bulk oxidant. 2. The method according to claim 1 , wherein the alcohol is a secondary alcohol.3. The method according to claim 1 , wherein the bulk oxidant is a peracid claim 1 , hydrogen peroxide claim 1 , a hypohalogen acid or a salt thereof claim 1 , a perhalogen acid or a salt thereof claim 1 , a persulfuric acid salt claim 1 , a halogenating agent such as a halide and N-bromosuccinimide claim 1 , a trihalogenated isocyanuric acid claim 1 , a diacetoxyiodoallene claim 1 , a dialkyl azodicarboxylate claim 1 , oxygen claim 1 , air claim 1 , or a mixture thereof.4. The method according to claim 1 , wherein the bulk oxidant is air.5. The method according to claim 2 , wherein the bulk oxidant is a peracid claim 2 , hydrogen peroxide claim 2 , a hypohalogen acid or a salt thereof claim 2 , a perhalogen acid or a salt thereof claim 2 , a persulfuric acid salt claim 2 , a halogenating agent such as a halide and N-bromosuccinimide claim 2 , a trihalogenated isocyanuric acid claim 2 , a diacetoxyiodoallene claim 2 , a dialkyl azodicarboxylate claim 2 , oxygen claim 2 , air claim 2 , or a mixture thereof.6. The method according to claim 2 , wherein the bulk oxidant is air. The present invention relates to a method for oxidizing an alcohol utilizing an organic catalyst.Oxidation reactions of alcohols constitute one class of important reactions as methods for chemical conversion of compounds, and are frequently used in syntheses of organic compounds with high added values such as medicaments and agricultural chemicals and the like. Therefore variety of methods have been developed so far. However, many of those methods use explosive reagents, highly toxic metals and the ...

Подробнее
18-07-2013 дата публикации

METHOD AND COMPOSITIONS FOR THE DETECTION OF PROTEIN GLYCOSYLATION

Номер: US20130183712A1
Принадлежит: California Institute of Technology

The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engine˜red mutant of β-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes. 2. The compound of claim 1 , wherein R is selected from the group consisting of straight chain or branched C-Ccarbon chain bearing a carbonyl group claim 1 , azide group claim 1 , straight chain or branched C-Ccarbon chain bearing an azide group claim 1 , straight chain or branched C-Ccarbon chain bearing an alkyne claim 1 , and straight chain or branched C-Ccarbon chain bearing an alkene.4. A labeled protein obtained from contacting a post-translationally modified protein comprising a pendant moiety with a labeling agent capable of reacting with the pendant moiety in the presence of an enzyme claim 1 , wherein the labeling agent comprises a chemical handle; and reacting the chemical handle with a detection agent.5. The labeled protein of claim 4 , wherein the pendant moiety is a glycosyl group.6. The method of claim 5 , wherein the glycosyl group is selected from the group consisting of glucose claim 5 , galactose claim 5 , mannose claim 5 , fucose claim 5 , GalNAc claim 5 , GlcNAc ...

Подробнее
18-07-2013 дата публикации

METHOD FOR PREPARING RIBONUCLEOSIDE PHOSPHOROTHIOATE

Номер: US20130184450A1
Автор: Nukaga Yohei, Wada Takeshi
Принадлежит: THE UNIVERSITY OF TOKYO

A method for preparing a phosphorothioate RNA based on the oxazaphospholidine method, wherein cyanoethoxymethyl group is used instead of tert-butyldimethylsilyl group as a protective group of 2′-hydroxyl group of RNA. 2. The method according to claim 1 , wherein Ris a phenyl group.3. The method according to claim 1 , wherein Ris a 4 claim 1 ,4′-dimethoxytrityl group.4. The method according to claim 1 , wherein the condensation is performed in the presence of an activator.5. The method according to claim 4 , wherein N-(cyanomethyl)pyrrolidinium triflate or N-phenylimidazolium triflate is used as the activator.6. The method according to claim 1 , wherein dimethyl thiuram disulfide is used as a sulfurizing agent.7. The method according to claim 1 , which comprises the step of repeating the aforementioned step n+1 times using a compound represented by the general formula (III) in which n is 0 as a starting material.8. The method according to claim 1 , wherein the reaction is performed by the solid phase method.9. The method according to claim 8 , wherein a compound represented by the formula (III) claim 8 , in which n is 0 and which is bound to a solid phase carrier optionally via a linker claim 8 , is used.10. The method according to claim 1 , wherein all of n+1 of X are divalent groups represented by the formula (II-Sp) claim 1 , or all of them are divalent groups represented by the formula (II-Rp).11. A ribonucleoside phosphorothioate represented by the formula (I) mentioned in claim 1 , wherein claim 1 , R claim 1 , Bs claim 1 , n claim 1 , and X have the same meanings as those defined above claim 1 , and Rrepresents a cyanoethoxymethyl group claim 1 , or a salt thereof.12. An oxazaphospholidine ribonucleoside represented by the formula (IVa) or (IVb) mentioned in claim 1 , wherein claim 1 , Bs claim 1 , CEM claim 1 , R claim 1 , and Rhave the same meanings as those defined above. The present invention relates to a method for stereoselectively preparing a ...

Подробнее
01-08-2013 дата публикации

Anhydrous polymorphs of [(2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof

Номер: US20130196940A1
Автор: William K. Mcvicar
Принадлежит: Inotek Pharmaceuticals Corp

The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate (Compound A). The present invention also provides processes for preparation of the anhydrous polymorphic forms of compound A.

Подробнее
01-08-2013 дата публикации

OLIGOMERIC COMPOUNDS COMPRISING TRICYCLIC NUCELOSIDES AND METHODS FOR THEIR USE

Номер: US20130197062A1
Принадлежит: Isis Pharmaceuticals, Inc.

The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. 2. The oligomeric compound of wherein qand qare H for each of said tricyclic nucleosides having formula II.3. The oligomeric compound of wherein at least one of q claim 1 , q claim 1 , qand qis other than H for each of said tricyclic nucleosides having formula II.4. The oligomeric compound of wherein at least one of q claim 1 , q claim 1 , qand qis fluoro for each of said tricyclic nucleosides having formula II.5. The oligomeric compound of wherein at least one of qand qis fluoro for each of said tricyclic nucleosides having formula II.6. The oligomeric compound of wherein at least one of qand qis fluoro for each of said tricyclic nucleosides having formula II.7. The oligomeric compound of wherein qand qare each fluoro for each of said tricyclic nucleosides having formula II.8. The oligomeric compound of wherein at least one of q claim 2 , q claim 2 , qand qis C-Calkyl for each of said tricyclic nucleosides having formula II.9. The oligomeric compound of wherein at least one of q claim 8 , q claim 8 , qand qis methyl for each of said tricyclic nucleosides having formula II.10. The oligomeric compound of wherein each q claim 1 , q claim 1 , qand qis H.11. The oligomeric compound of wherein zis fluoro for each of said tricyclic nucleosides having formula II.12. The oligomeric compound of wherein zis fluoro for each of said tricyclic nucleosides having formula II.13. The oligomeric compound of wherein zand zare each fluoro for each of said tricyclic nucleosides having formula II.14. The oligomeric compound of claim 1 , wherein at ...

Подробнее
08-08-2013 дата публикации

COMPOUNDS FOR TREATING BACTERIAL INFECTIONS

Номер: US20130203694A1

Rel proteins as a novel therapeutic agent for treating bacterial threats. More specifically, a novel class of compounds of Formula (I) as disclosed herein which possess anti-bacterial activity and which inhibit RelA, RelSeq or RelSpo synthetic activity or bacterial spore formation. Also, pharmaceutical compositions of such compounds and a method of combating bacteria, or treating bacterial infections, by administering to a subject in need thereof such compounds or pharmaceutical compositions. 143.-. (canceled)47. The compound according to claim 44 , wherein Ris H or —CO—CH(CH).49. The compound according to claim 44 , wherein Rand Rare each independently H or methyl.50. The compound according to claim 44 , wherein Ris independently at each occurrence H claim 44 , methyl claim 44 , ethyl or benzyl.51. The compound according to claim 44 , wherein Ris H or phenyl.63. An anti-bacterial pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 44 , and a pharmaceutically acceptable carrier or excipient.64. A method of combating bacteria claim 44 , or treating bacterial infections claim 44 , comprising the step of administering to a subject in need thereof a compound according to claim 44 , or a pharmaceutical composition comprising such compound. The present invention generally relates to Rel proteins as a novel therapeutic target for treating bacterial threats and more specifically to a novel class of 2′-deoxyguanosine analogs, which possess anti-bacterial activity, to pharmaceutical compositions comprising such compounds, and to methods of use thereof for combating bacteria and treating bacterial infections.Bacteria cells present an outstanding ability to rapidly react to various changes in their growth environment. The number of useful antibiotic agents is decreasing fast. Thus, there is an urgency for finding alternative ways to deal with the crisis.The natural environment of bacteria is often characterized by changes in ...

Подробнее
08-08-2013 дата публикации

2' AND 5' MODIFIED MONOMERS AND OLIGONUCLEOTIDES

Номер: US20130203836A1
Принадлежит:

The present invention provides nucleosides of formula (1) and oligonucleotides comprising at least on nucleoside of formula (2):Formula (1) and Formula (2). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene. 10. The oligonucleotide of claim 5 , wherein at least one of Tand Tis methyl.11. The oligonucleotide of claim 5 , wherein one of Tand Tis methyl and the other of T claim 5 , and Tis H.12. The oligonucleotide of wherein Xis O.13. The oligonucleotide of wherein Xis S.14. The oligonucleotide of wherein Xis CHor CF.15. The oligonucleotide of wherein the oligonucleotide comprises:1-20 first-type regions, each first-type region independently comprising 1-20 contiguous nucleosides wherein each nucleoside of each first-type region comprises a first-type modification;0-20 second-type regions, each second-type region independently comprising 1-20 contiguous nucleosides wherein each nucleoside of each second-type region comprises a second-type modification; and0-20 third-type regions, each third-type region independently comprising 1-20 contiguous nucleosides wherein each nucleoside of each third-type region comprises a third-type modification;{'sub': 3', '2', '3, 'wherein the first-type modification, the second-type modification, and the third-type modification are each independently selected from the group consisting of 2′-F, 2′-OCH, 2′-O(CH)2OCH, BNA, F-HNA, 2′-H and 2′-OH.'}16. The oligonucleotide of claim 5 , wherein the oligonucleotide comprises at least one non-phosphodiester internucleoside linkage.17. The oligonucleotide of claim 16 , wherein at least one of the non-phosphodiester internucleoside linkage is selected from the group consisting of phosphorothioate claim 16 , phosphorodithioate claim 16 , alkyl- ...

Подробнее
08-08-2013 дата публикации

NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY

Номер: US20130203978A1
Автор: Wagner Carston R.
Принадлежит: Regents of the University of Minnesota

The invention provides a compound of formula (I), wherein R1-R6 and X have any of the values described, as well as pharmaceutical compositions comprising such compounds and therapeutic methods comprising the administration of such compounds. 2. The compound of wherein Ris guanine.3. The compound of wherein Ris NRR claim 1 , wherein Ris phenylmethyl and Ris hydrogen.4. The compound of wherein Ris (C-C)alkyl optionally substituted with one or more halo claim 1 , hydroxy claim 1 , (C-C)alkoxy claim 1 , (C-C)cycloalkyloxy claim 1 , (C-C)alkanoyloxy claim 1 , trifluoromethyl claim 1 , azido claim 1 , cyano claim 1 , (C-C)alkyl claim 1 , (C-C)cycloalkyl claim 1 , (C-C)cycloalkyl(C-C)alkyl claim 1 , (C-C)alkyl-S—(C-C)alkyl- claim 1 , aryl claim 1 , Het claim 1 , aryl(C-C)alkyl claim 1 , or Het(C-C)alkyl claim 1 , or NRR; wherein each Rand Ris independently hydrogen claim 1 , (C-C)alkyl claim 1 , (C-C)cycloalkyl claim 1 , phenyl claim 1 , benzyl claim 1 , or phenethyl.5. The compound of wherein Ris (C-C)alkyl optionally substituted with one or more halo claim 1 , hydroxy claim 1 , (C-C)alkoxy claim 1 , (C-C)alkanoyloxy claim 1 , trifluoromethyl claim 1 , cyano claim 1 , aryl claim 1 , or Het.6. The compound of wherein Ris (C-C)alkyl optionally substituted with one or more aryl or Het.7. The compound of wherein Ris (C-C)alkyl substituted with a phenyl claim 6 , naphthyl claim 6 , pyridyl claim 6 , indolyl claim 6 , isoindolyl claim 6 , furyl claim 6 , thienyl claim 6 , pyrrolyl claim 6 , benzofuranyl claim 6 , benzothienyl claim 6 , imidazolyl claim 6 , thiazoyl claim 6 , pyrrolidinyl claim 6 , piperidinyl claim 6 , piperazinyl claim 6 , or morpholino ring claim 6 , which ring is optionally substituted with one or more substituents selected from the group consisting of halo claim 6 , hydroxy claim 6 , (C-C)alkyl claim 6 , (C-C)cycloalkyl claim 6 , (C-C)alkoxy claim 6 , (C-C)cycloalkyloxy claim 6 , (C-C)alkanoyl claim 6 , (C-C)alkanoyloxy claim 6 , trifluoromethyl claim 6 , ...

Подробнее
15-08-2013 дата публикации

Methods for the Identification of Methyltransferase Interacting Molecules and for the Purification of Methyltransferase Proteins

Номер: US20130210664A1
Принадлежит: Cellzome AG

The present invention relates to immobilization compounds, immobilization products and preparations thereof as well as methods and uses for the identification of methyltransferase interacting compounds or for the purification or identification of methyltransferase proteins. 3. A method for the preparation of an immobilization product claim 1 , wherein the immobilization compound of is immobilized on a solid support claim 1 , in particular wherein the solid support is selected from the group consisting of agarose claim 1 , modified agarose claim 1 , sepharose beads (e.g. NHS-activated sepharose) claim 1 , latex claim 1 , cellulose claim 1 , and ferro- or ferrimagnetic particles.4. The method of claim 3 , wherein the immobilization product results from a covalent direct or linker mediated attachment of the immobilization compound to the solid support claim 3 , in particular wherein the linker is a Calkylene group claim 3 , which is optionally interrupted or terminated by one or more atoms or functional groups selected from the group consisting of S claim 3 , O claim 3 , NH claim 3 , C(O)O claim 3 , OC(O) claim 3 , C(O) claim 3 , NHC(O) claim 3 , and C(O)NH and wherein the linker is optionally substituted with one or more substituents independently selected from the group consisting of halogen claim 3 , OH claim 3 , NH claim 3 , C(O)H claim 3 , C(O)NH claim 3 , SOH claim 3 , NO claim 3 , and CN.5. (canceled)6. An immobilization product claim 1 , comprising the immobilization compound of immobilized on a solid support claim 1 , in particular wherein the solid support is selected from the group consisting of agarose claim 1 , modified agarose claim 1 , sepharose beads (e.g. NHS-activated sepharose) claim 1 , latex claim 1 , cellulose claim 1 , and ferro- or ferrimagnetic particles.7. A method for the identification of a methyltransferase interacting compound claim 1 , comprising the steps ofa) providing a protein preparation containing a variety of methyltransferases,{' ...

Подробнее
15-08-2013 дата публикации

DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS

Номер: US20130210757A1
Автор: Huang Qiang, Liu Runcong
Принадлежит: Nanjing Molecular Research, Inc.

This application discloses phosphoramidate and phosphonoamidate prodrugs of alcohol-based therapeutic agents, such as nucleosides, nucleotides, acyclonucleosides, C-nucleosides, and C-nucleotides, and use of these prodrugs for treatment of diseases or disorders, including infectious diseases and cancers. This application also discloses a general method for enhancing bioavailability and/or liver-targeting property of alcohol drugs through converting the alcohol drugs to phosphoramidate or phosphonoamidate prodrugs, and methods of preparation of these prodrugs. 6. The compound of claim 1 , wherein Y is a nucleoside moiety claim 1 , or a pharmaceutically acceptable salt or solvate thereof.7. The compound of claim 1 , wherein Ris M claim 1 , and Y is a nucleoside moiety claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , wherein M is selected from the group consisting of NH claim 1 , K claim 1 , Na claim 1 , Ca claim 1 , and Mg.11. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , wherein X is CH claim 1 , or a pharmaceutically acceptable salt or solvate thereof.12. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , wherein X is O claim 1 , and Y is a moiety of an acyclic nucleoside selected from the group consisting of acyclovir claim 1 , ganciclovir and pencyclovir.13. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , wherein X is O claim 1 , and Y is a moiety of a C-nucleoside comprising a nucleic base and a sugar moiety connected with each other through a carbon-carbon bond.16. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof claim 1 , and a pharmaceutically acceptable carrier or diluent.17. A method of treating a viral infection or cancer claim 1 , comprising administration of a compound of claim 1 , or a pharmaceutically acceptable salt or ...

Подробнее
15-08-2013 дата публикации

PURIFICATION OF SYNTHETIC OLIGONUCLEOTIDES

Номер: US20130211065A1
Автор: Fang Shiyue
Принадлежит: MICHIGAN TECHNOLOGICAL UNIVERSITY

This invention provides a method for purifying synthetic oligonucleotides comprising capping, polymerizing and separating any failure sequences produced during oligonucleotide synthesis. The invention also provides a method for purifying synthetic oligonucleotides comprising reacting a full length oligonucleotide with a compound to attach a polymerizable functional group to an end of the full length oligonucleotide, polymerizing the full length oligonucleotides and removing the failure sequences, and recovering the full length oligonucleotides. The invention also provides novel capping agents having a polymerizable functional group, and kits comprising at least one composition of the present invention. 2. The method of claim 1 , wherein Ris hydrogen.5. The method of claim 4 , wherein Ar is 1 claim 4 ,4-phenylenyl.6. The method of claim 4 , wherein Y is —O—.7. The method of claim 1 , wherein the failure sequences are polymerized via radical acrylamide polymerization.8. The method of claim 1 , wherein linker is (CH).9. The method of claim 1 , wherein Ris —N(CH(CH)).10. The method of claim 1 , wherein Ris —CH—-CH—CN.11. The method of claim 1 , wherein Ris methyl.12. The method of claim 1 , wherein Rand Rare each hydrogen.14. The method of claim 13 , wherein Rand Rare each hydrogen.17. The method of claim 16 , wherein Ris hydrogen.18. The method of claim 16 , wherein Ar is 1 claim 16 ,4-phenylenyl.19. The method of claim 16 , wherein Y is —O—.20. The method of claim 13 , wherein linker is (CH).22. The method of claim 21 , wherein Ris hydrogen.25. The method of claim 24 , wherein Ar is 1 claim 24 ,4-phenylenyl.26. The method of wherein Y is —O—.28. The method of claim 27 , wherein Ris hydrogen.29. The method of claim 27 , wherein Y is —O—.32. The method of claim 31 , wherein Ar is 1 claim 31 ,4-phenylenyl.33. The method of claim 31 , wherein Y is —O—.34. The method of claim 31 , wherein Z is —O—.36. The method of claim 13 , wherein Ris —N(CH(CH)).37. The method of claim ...

Подробнее
22-08-2013 дата публикации

METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS

Номер: US20130217643A1
Принадлежит: INOTEK PHARMACEUTICALS CORPORATION

Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for reducing intraocular pressure comprising administering an effective amount of compounds of Formula I to a subject in need thereof. 118-. (canceled)19. A method of treating diseases and conditions caused by elevated intraocular pressure (IOP) in a human subject in need thereof by administering an effective amount of a selective adenosine Aagonist to an affected eye of the subject.20. The method of claim 19 , wherein the diseases and conditions caused by elevated IOP in a human are selected from the group consisting of normal-tension glaucoma claim 19 , ocular hypertension (OHT) claim 19 , and primary open-angle glaucoma (POAG).24. The method as claimed in wherein the selective adenosine Aagonist is selected from the group consisting of:((2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate;((2R,3S,4R,5R)-5-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate;sodium ((2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl sulfate; and((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-(tetrahydrofuran-3-ylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl nitrate.25. The method as claimed in wherein the IOP of the affected eye is reduced by at least 10%.26. The method as claimed in wherein the IOP of the affected eye is reduced by about 10-20%.27. The method as claimed in wherein the IOP of the affected eye is reduced by 20% or more.28. The method as claimed in wherein the IOP of the affected eye is reduced by at least 10% for more than 3 hours.29. The method as claimed in wherein the IOP of the affected eye is reduced by about 10-20% for more than 3 hours.30. The method as claimed in wherein the IOP of the affected eye is reduced by 20% or more for more than 3 hours.31. The method as claimed in wherein the IOP of the affected eye ...

Подробнее
22-08-2013 дата публикации

Uracyl Spirooxetane Nucleosides

Номер: US20130217648A1
Принадлежит:

Compounds of the formula I: 212-. (canceled)13. The compound of claim 1 , wherein Ris a monophosphate ester.14. A pharmaceutical composition comprising an anti-virally effective amount of a compound of and a pharmaceutically acceptable carrier.15. A method for inhibiting HCV claim 13 , comprising administering to a patient in need thereof an effective amount of a compound of .16. The compound of claim 1 , wherein Ris a diphosphate ester.17. A pharmaceutical composition comprising an anti-virally effective amount of a compound of and a pharmaceutically acceptable carrier.18. A method for inhibiting HCV claim 16 , comprising administering to a patient in need thereof an effective amount of a compound of .19. The compound of claim 1 , wherein Ris a triphosphate ester.20. A pharmaceutical composition comprising an anti-virally effective amount of a compound of and a pharmaceutically acceptable carrier.21. A method for inhibiting HCV claim 19 , comprising administering to a patient in need thereof an effective amount of a compound of . This invention relates to uracyl spirooxetane nucleosides that are inhibitors of the hepatitis C virus (HCV).HCV is a single stranded, positive-sense RNA virus belonging to the family of viruses in the hepacivirus genus. The NS5B region of the RNA polygene encodes a RNA dependent RNA polymerase (RdRp), which is essential to viral replication. Following the initial acute infection, a majority of infected individuals develop chronic hepatitis because HCV replicates preferentially in hepatocytes but is not directly cytopathic. In particular, the lack of a vigorous T-lymphocyte response and the high propensity of the virus to mutate appear to promote a high rate of chronic infection. Chronic hepatitis can progress to liver fibrosis, leading to cirrhosis, end-stage liver disease, and HCC (hepatocellular carcinoma), making it the leading cause of liver transplantations. There are six major HCV genotypes and more than 50 subtypes, which are ...

Подробнее
29-08-2013 дата публикации

Uracyl Spirooxetane Nucleoside Phosphoramidates

Номер: US20130225520A1
Принадлежит:

This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate which inhibits the hepatitis C virus (HCV). 2. The compound wherein said compound is a salt form.3. The compound of wherein the salt is a pharmaceutically acceptable salt.4. The compound of wherein said compound is a solvated form.5. The compound of having a stereoisomeric excess of at least 80%.6. The compound of having a stereoisomeric excess of at least 90%.7. The compound of having a stereoisomeric excess of at least 94%.8. A pharmaceutical composition comprising an anti-virally effective amount of a compound of claim 4 , and a pharmaceutically acceptable carrier.910-. (canceled)11. A method for treating a hepatitis C virus infection comprising contacting a cell with the compound of . This invention relates to an uracyl spirooxetane nucleoside phosphoramidate useful in the treatment of patients infected with the hepatitis C virus (HCV).HCV is a single stranded, positive-sense RNA virus belonging to the Flaviviridae family of viruses in the hepacivirus genus. The NS5B region of the RNA polygene encodes a RNA dependent RNA polymerase (RdRp), which is essential to viral replication. Following the initial acute infection, a majority of infected individuals develop chronic hepatitis because HCV replicates preferentially in hepatocytes but is not directly cytopathic. In particular, the lack of a vigorous T-lymphocyte response and the high propensity of the virus to mutate appear to promote a high rate of chronic infection. Chronic hepatitis can progress to liver fibrosis, leading to cirrhosis, end-stage liver disease, and HCC (hepatocellular carcinoma), making it the leading cause of liver transplantations. There are six major HCV genotypes and more than 50 subtypes, which are differently distributed geographically. HCV genotype 1 is the predominant genotype in Europe and in the US. The extensive genetic heterogeneity of HCV has important diagnostic and clinical ...

Подробнее
12-09-2013 дата публикации

Cdk-inhibiting pyrrolopyrimidinone carboxamide derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing the same as active ingredient for preventing or treating hepatocellular carcinoma

Номер: US20130237495A1
Принадлежит: SNU R&DB FOUNDATION

The present invention relates to a CDK-inhibiting pyrrolopyrimidinone carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing same as an active ingredient for preventing or treating liver cell cancer, and the composition containing the pyrrolopyrimidinone carboxamide derivative of the present invention suppresses the cell growth of SNU-354 cell, which is a liver cancer stem cell in humans, by inhibiting CDK1 and CDK2, and induces cell apoptosis of the cell by inhibiting CDK7 and CDK 7, and thus can be effective in use for preventing or treating liver cell cancer.

Подробнее
19-09-2013 дата публикации

2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT

Номер: US20130243725A1
Принадлежит: Gilead Sciences, Inc.

Provided are compounds of Formula I, 3. The compound of claim 2 , wherein Ris H.5. The compound of claim 1 , wherein Ris H claim 1 , CHOH claim 1 , CHF claim 1 , CHF claim 1 , CH═CH claim 1 , C≡CH claim 1 , CN claim 1 , CHCH═CH claim 1 , N claim 1 , CH claim 1 , or CHCH.6. The compound of claim 5 , wherein Ris H.7. The compound of claim 1 , wherein Ris OH or O-benzyl.8. The compound of claim 7 , wherein Ris OH.9. The compound of claim 1 , wherein Ris F or N.10. The compound of claim 9 , wherein Ris F.11. The compound of claim 1 , wherein Ris NHand Ris H claim 1 , F claim 1 , Cl claim 1 , Br claim 1 , N claim 1 , CN claim 1 , CF claim 1 , NH claim 1 , SMe claim 1 , or SOMe.12. The compound of claim 1 , wherein Ris NHand Ris ═O claim 1 , OH claim 1 , OMe claim 1 , Cl claim 1 , Br claim 1 , I claim 1 , NH claim 1 , NHMe claim 1 , NHcPr or SMe.13. The compound of claim 1 , wherein each of Rand Ris independently selected from the group consisting of H claim 1 , NH claim 1 , ═O claim 1 , NHMe claim 1 , NHcPr claim 1 , OH claim 1 , OMe claim 1 , Cl claim 1 , Br claim 1 , I claim 1 , SMe claim 1 , F claim 1 , N claim 1 , CN claim 1 , CF claim 1 , and SOMe.14. The compound of claim 13 , wherein Ris H or NH.15. The compound of claim 13 , wherein Ris ═O or NH.17. The compound of claim 16 , wherein Ris H.18. The compound of claim 1 , wherein Ris H or OH.19. The compound of claim 18 , wherein Ris H.20. The compound of claim 1 , wherein Ris H claim 1 , Ris OH and Ris F.21. The compound of claim 20 , wherein Rand Rare NH claim 20 , H or ═O claim 20 , and Rand Rare hydrogen.25. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a therapeutically effective amount of a compound of , and a pharmaceutically acceptable carrier or excipient.'}26. The pharmaceutical composition of further comprising at least one additional therapeutic agent.27. The pharmaceutical composition of claim 26 , wherein the at least one additional therapeutic agent is ...

Подробнее
19-09-2013 дата публикации

Uracyl Spirooxetane Nucleoside Phosphoramidates

Номер: US20130244968A1
Принадлежит:

This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate useful in the treatment of patients infected with the hepatitis C virus (HCV). 2. The compound of claim 1 , wherein said compound is a salt.3. The compound of wherein the salt is a pharmaceutically acceptable salt.4. The compound of claim 1 , wherein said compound is a solvate.5. The compound of claim having a stereoisomeric excess of at least 80%.6. The compound of having a stereoisomeric excess of at least 90%.7. The compound of having a stereoisomeric excess of at least 94%.8. A pharmaceutical composition comprising an anti-virally effective amount of the compound of claim claim 6 , and a pharmaceutically acceptable carrier.910-. (canceled)11. A method for treating a hepatitis C virus infection comprising contacting a cell with the compound of . This invention relates to an uracyl spirooxetane nucleoside phosphoramidate useful in the treatment of patients infected with the hepatitis C virus (HCV).HCV is a single stranded, positive-sense RNA virus belonging to the Flaviviridae family of viruses in the hepacivirus genus. The NS5B region of the RNA polygene encodes a RNA dependent RNA polymerase (RdRp), which is essential to viral replication. Following the initial acute infection, a majority of infected individuals develop chronic hepatitis because HCV replicates preferentially in hepatocytes but is not directly cytopathic. In particular, the lack of a vigorous T-lymphocyte response and the high propensity of the virus to mutate appear to promote a high rate of chronic infection. Chronic hepatitis can progress to liver fibrosis, leading to cirrhosis, end-stage liver disease, and HCC (hepatocellular carcinoma), making it the leading cause of liver transplantations. There are six major HCV genotypes and more than 50 subtypes, which are differently distributed geographically. HCV genotype 1 is the predominant genotype in Europe and in the US. The extensive genetic ...

Подробнее
26-09-2013 дата публикации

PHOSPHORAMIDITE DERIVATIVES OF GEMCITABINE FOR USE IN THE TREATMENT CANCER

Номер: US20130252918A1
Автор: McGuigan Christopher
Принадлежит:

Phosphorodiamidate derivatives of e.g. gemcitabine are provided for use in treating cancer. In one embodiment, the two amidate motifs each comprises NR′R″ where R′ is H and R″ is CRRCOR, where Ris H, Ris the side chain, including H and C, of a naturally occurring alpha amino acid, and Ris branched or unbranched, substituted or unsubstituted, acyclic or cyclic alkyl, including t-butyl-CH2-, benzyl and Cto Ccycloalkyl. Formula (I). 2. A compound according to where Rand Rare the same.3. A compound according to where Rand Rare each CRRCOR.4. A compound according to wherein Ris selected from the group comprising branched and unbranched C-Cacyclic alkyl and C-Ccyclic alkyl claim 1 , any of which acyclic alkyl and cyclic alkyl moieties may be substituted and/or unsaturated.5. A compound according to wherein Ris selected from methyl claim 4 , ethyl claim 4 , i-propyl claim 4 , t-butyl-CH— claim 4 , benzyl and C-Ccycloalkyl.6. A compound according to where Ris t-butyl-CH—.7. A compound according to wherein Ris H and Ris selected from the side chains of naturally occurring alpha amino acids.8. A compound according to wherein Ris H and Ris selected from H claim 7 , methyl claim 7 , i-propyl claim 7 , —CHPh claim 7 , —CHCH(CH)and —CH(CH)(CH).9. A compound according to wherein Ris H and Ris methyl.10. A compound according to wherein Ris selected from methyl claim 9 , ethyl claim 9 , i-propyl claim 9 , t-butyl-CH— claim 9 , benzyl and C-Ccycloalkyl.11. A compound according to wherein Ris t-butyl-CH—.12. A compound according to where the compound has natural L stereochemistry at *CRR.13. A compound according to wherein the compound has D stereochemistry at *CRR.14. A compound according to wherein each of Rand Ris methyl.15. A compound according to wherein each of Rand Ris the same.16. A compound according to wherein each of Rand Ris H.17. A compound according to wherein each of Rand Ris H and each of Rand Ris CRRCOR.18. A compound according to wherein each of Rand Ris H and each ...

Подробнее
26-09-2013 дата публикации

Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders

Номер: US20130252919A1
Принадлежит: TUFTS UNIVERSITY

This disclosure relates to uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P 2 Y 6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.

Подробнее
26-09-2013 дата публикации

2'-O-MODIFIED RNA

Номер: US20130253178A1
Принадлежит:

[Problem] 2. The ribonucleoside claim 1 , the ribonucleotide claim 1 , or the derivative thereof having a protective group at the 2′-position according to claim 1 ,{'sup': '4', 'wherein R′ to Rmay be identical or different, and each represents a hydrogen atom, a methyl group or an ethyl group,'}{'sup': 5', '6, 'sub': '1-3', 'Rand Rmay be identical or different, and each represents a hydrogen atom, a halogen atom, or a Chaloalkyl group, and'}{'sup': '7', 'Rrepresents a halogen atom.'}3. The ribonucleoside claim 1 , the ribonucleotide claim 1 , or the derivative thereof having a protective group at the 2′-position according to claim 1 ,{'sup': 1', '4, 'wherein all of Rto Rrepresent a hydrogen atom,'}{'sup': 5', '6, 'Rand Rmay be identical or different, and each represents a hydrogen atom, a fluorine atom, a chlorine atom or a bromine atom, and'}{'sup': '7', 'Rrepresents a fluorine atom, a chlorine atom or a bromine atom.'}4. The ribonucleoside claim 1 , the ribonucleotide claim 1 , or the derivative thereof having a protective group at the 2′-position according to claim 1 ,{'sup': 1', '5, 'wherein all of Rto Rrepresent a hydrogen atom,'}{'sup': '6', 'Rrepresents a hydrogen atom, a fluorine atom or a chlorine atom, and'}{'sup': '7', 'Rrepresents a fluorine atom or a chlorine atom.'}5. The ribonucleoside claim 1 , the ribonucleotide claim 1 , or the derivative thereof having a protective group at the 2′-position according to claim 1 ,{'sup': 1', '5, 'wherein all of Rto Rrepresent a hydrogen atom,'}{'sup': '6', 'Rrepresents a hydrogen atom, or a chlorine atom, and'}{'sup': '7', 'Rrepresents a chlorine atom.'}6. The ribonucleoside claim 1 , the ribonucleotide claim 1 , or the derivative thereof having a protective group at the 2′-position according to claim 1 , which is2′-O-(2-chloro)ethoxymethyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)nucleic acid base B,2′-O-(2,2-dichloro)ethoxymethyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxane-1,3diyl)nucleic acid base B,2′-O-( ...

Подробнее
26-09-2013 дата публикации

Methods of preparing substituted nucleotide analogs

Номер: US20130253181A1

Disclosed herein are methods of preparing a phosphorothioate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections.

Подробнее
03-10-2013 дата публикации

Conformationally restricted dinucleotide monomers and oligonucleotides

Номер: US20130260460A1
Принадлежит: ISIS PHARMACEUTICALS INC

This invention relates to conformationally locked dinucleotide motifs for exo- and phosphate stabilization. For instance, oligonucleotides can be prepared having one or more of the following formulas (IV-IX).

Подробнее
10-10-2013 дата публикации

DNA SEQUENCING BY SYNTHESIS USING MODIFIED NUCLEOTIDES AND NANOPORE DETECTION

Номер: US20130264207A1
Принадлежит:

This disclosure is related to a method of sequencing a single-stranded DNA using deoxynucleotide polyphosphate analogues and translocation of tags from incorporated deoxynucleotide polyphosphate analogues through a nanopore. 5. The method of claim 1 , wherein the tag is ethylene glycol claim 1 , an amino acid claim 1 , a carbohydrate claim 1 , a dye claim 1 , a mononucleotide claim 1 , a dinucleotide claim 1 , a trinucleotide claim 1 , a tetranucleotide claim 1 , a pentanucleotide or a hexanucleotide claim 1 , a fluorescent dyes claim 1 , a chemiluminiscent compound claim 1 , an amino acid claim 1 , a peptide claim 1 , a carbohydrate claim 1 , a nucleotide monophopshate claim 1 , a nucleotide diphosphate claim 1 , an aliphatic acid or an aromatic acid or an alcohol or a thiol with unsubstituted or substituted with one or more halogens claim 1 , a cyano group claim 1 , a nitro group claim 1 , an alkyl group claim 1 , an alkenyl group claim 1 , an alkynyl group claim 1 , an azido group.6. The method of claim 1 , wherein the base is selected from the group consisting of adenine claim 1 , guanine claim 1 , cytosine claim 1 , thymine claim 1 , 7-deazaguanine claim 1 , 7-deazaadenine or 5-methylcytosine.7. The method of claim 1 , further comprising a washing step after each iteration of step (b) to remove unincoporated dNPP analogues from contact with the single-stranded DNA.8. (canceled)9. The method of claim 1 , wherein the single-stranded DNA claim 1 , electrolyte solution and nanopore in the membrane are located within a single container.1011-. (canceled)13. The method of claim 1 , wherein the tag is a mononucleotide claim 1 , a dinucleotide claim 1 , a trinucleotide claim 1 , a tetranucleotide claim 1 , a pentanucleotide or a hexanucleotide and wherein the base of the mononucleotide claim 1 , a dinucleotide claim 1 , a trinucleotide claim 1 , a tetranucleotide claim 1 , a pentanucleotide or a hexanucleotide is the same type of base as the base of the dNPP analogue. ...

Подробнее
10-10-2013 дата публикации

Solid Forms of a Thiophosphoramidate Nucleotide Prodrug

Номер: US20130266538A1
Принадлежит:

The present application relates to solid state forms, for example, crystalline forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents. 185-. (canceled)86. 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate characterized as Form J.87. Form J of claim 86 , wherein the Form J is characterized by one or more peaks in an X-ray powder diffraction pattern claim 86 , wherein the one or more peaks is selected from a peak from about 5.9 to about 6.3 degrees claim 86 , a peak from about 7.3 to about 7.7 degrees claim 86 , a peak from about 11.9 to about 12.3 degrees claim 86 , a peak from about 13.1 to about 13.5 degrees claim 86 , a peak from about 13.8 to about 14.2 degrees claim 86 , a peak from about 18.3 to about 18.7 degrees claim 86 , a peak from about 22.4 to about 22.8 degrees claim 86 , a peak from about 33.0 to about 33.4 degrees claim 86 , a peak from about 33.8 to about 34.2 degrees claim 86 , and a peak from about 35.1 to about 35.5 degrees.88. Form J of claim 86 , wherein the Form J is characterized by one or more peaks in an X-ray powder diffraction pattern claim 86 , wherein the one or more peaks is selected from a peak at about 6.1 degrees claim 86 , a peak at about 7.5 degrees claim 86 , a peak at about 12.1 degrees claim 86 , a peak at about 13.3 degrees claim 86 , a peak at about 14.0 degrees claim 86 , a peak ...

Подробнее
24-10-2013 дата публикации

SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR

Номер: US20130281682A1
Принадлежит: Girindus AG

A method for preparing a phosphitylated compound comprising the step of:—reacting a hydroxyl containing compound with a phosphitylating agent in the presence of an activator having the formula (I) wherein R=alkyl, cycloalkyl, aryl, aralkyl, heteroalkyl, heteroaryl R, R=either H or form a 5 to 6-membered ring together. X, X=independently either N or CH Y=H or Si(R), with R=alkyl, cycloalkyl, aryl, aralkyl, heteroalkyl, heteroaryl B=deprotonated acid. The hydroxyl containing compound is preferably a sugar moiety or a nucleoside or an oligomer derived therefrom. 118-. (canceled)21. The method of claim 19 , wherein said hydroxyl containing compound comprises a sugar moiety.22. The method of claim 19 , wherein said hydroxyl containing compound is a nucleoside or an oligomer derived therefrom.23. The method of claim 19 , wherein said hydroxyl containing compound is a 5′-O-protected nucleoside having a 3′-hydroxyl group or a 3′-O-protected nucleoside having a 5′-hydroxyl group.24. The method of claim 19 , wherein said activator is prepared in-situ and used without purification.26. The method of claim 25 , wherein claim 25 , prior to said reaction step claim 25 , said corresponding base is brought into contact with said hydroxyl containing compound and said phosphitylating agent and an acid HB is added.28. The method of claim 19 , wherein said phosphitylating agent is 2-cyanoethyl-N claim 19 ,N claim 19 ,N′ claim 19 ,N′-tetraisopropylphosphorodiamidite.29. The method of claim 19 , wherein B is selected from the group consisting of trifluoroacetate claim 19 , dichloroacetate claim 19 , mesylate claim 19 , triflate claim 19 , o-chlorophenolate claim 19 , and mixtures thereof.30. A phosphoramidite prepared according to the method of claim 19 , wherein said phosphoramidite is selected from the group consisting of adenosine phosphoramidite; cytosine phosphoramidite; guanosine phosphoramidite; uracil phosphoramidite; desoxyadenosine phosphoramidite; desoxyguanosine ...

Подробнее
24-10-2013 дата публикации

Methods of preparing substituted nucleotide analogs

Номер: US20130281687A1

Disclosed herein are methods of preparing a phosphorothioate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections.

Подробнее
31-10-2013 дата публикации

NUCLEOSIDE PHOSPHORAMIDATES

Номер: US20130288997A1
Принадлежит:

Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. 170.-. (canceled)72. A pharmaceutical composition comprising the crystalline compound according to and a pharmaceutically acceptable medium.73. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the crystalline compound according to .74. The method according to further comprising administering to the human another antiviral agent.76. The process according to further comprising:grinding the first composition into a powder; andallowing the powder to stand in an open vessel.78. The process according to further comprising heating the suspension.79. The process according to further comprising cooling the suspension. This application is a continuation-in-part of U.S. patent application Ser. No. 12/783,680 filed on May 20, 2010, which claims priority to U.S. 61/179,923, filed May 20, 2009 and U.S. 61/319,513, filed on Mar. 31, 2010. Priority is claimed to U.S. 61/319,513, filed on Mar. 31, 2010 and U.S. 61/319,548, filed Mar. 31, 2010.Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.Hepatitis C virus (HCV) infection is a major health problem that leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals, estimated to be 2-15% of the world's population. There are an estimated 4.5 million infected people in the United States alone, according to the U.S. Center for ...

Подробнее
31-10-2013 дата публикации

COMPOUND, NUCLEIC ACID, METHOD FOR PRODUCING NUCLEIC ACID, AND KIT FOR PRODUCING NUCLEIC ACID

Номер: US20130289263A1
Принадлежит: RIKEN

A compound is represented by the following formula (), (), or () (where, in the above formulae (), (), and (), Zand Zindependently have a fluorescent property and are an uncharged atomic group exhibiting an exciton effect). 3. The compound as set forth in claim 1 ,{'sup': 1', '2', '3, 'wherein main chains of R, R, and Rare independently constituted by two or more atoms.'}5. The compound as set forth in claim 4 ,{'sup': '4', 'wherein l, m, and n are 2, and Ris a double bond.'}7. The compound as set forth in claim 6 , wherein:{'sup': '31', 'Ris a polymethylene carbonyl group having two or more carbon atoms in the above formula (12), (28), and (29); and'}{'sup': 1', '2, 'a carbonyl group portion of the polymethylene carbonyl group having two or more carbon atoms is attached to Ror Rin the above formula (1), (2), or (3), or is attached to NH in the above formula (8), (9), (10), or (11).'}8. The compound as set forth in claim 1 ,{'sup': 41', '42', '43, 'wherein Ris a cyanoethyl group, both Rand Rare an isopropyl group.'}9. A method of producing a nucleic acid claim 1 , comprising:{'claim-ref': [{'@idref': 'CLM-00001', 'claim 1'}, {'@idref': 'CLM-00001', 'claim 1'}], 'carrying out a condensation reaction of a compound as recited in and an oligonucleic acid, the compound as recited in being such that G is a phosphoramidite group represented by the above formula (33).'}11. The nucleic acid as set forth in claim 1 , which is produced by a method as recited in .12. A kit for producing a nucleic acid claim 1 , comprising a compound as recited in .13. A method of producing a compound which is a compound as recited in where G is a phosphoramidite group represented by the above formula (33) claim 1 ,the method comprising the step of{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'phosphoroamidating, in an aprotic solvent, a compound which is recited in where G is a hydroxyl group.'} The present invention relates to a compound and a nucleic acid each of which contains a dye ...

Подробнее
21-11-2013 дата публикации

Modulators of Histone Methyltransferase, and Methods of Use Thereof

Номер: US20130310333A1
Принадлежит: EPIZYME, INC.

Disclosed are compounds, pharmaceutical compositions containing the compounds, and the uses of the compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity. 35-. (canceled)79-. (canceled)11. The compound of claim 10 , wherein Ris hydrogen or alkyl.12. (canceled)13. The compound of claim 10 , wherein Ris hydrogen claim 10 , alkyl claim 10 , —O-alkyl claim 10 , halogen claim 10 , trifluoroalkyl claim 10 , —O-trifluoromethyl claim 10 , or —SO-trifluoromethyl.14. The compound of claim 13 , wherein Ris hydrogen claim 13 , alkyl claim 13 , halogen claim 13 , or trifluoroalkyl.15. The compound of claim 14 , wherein Ris hydrogen claim 14 , alkyl claim 14 , or halogen; and Ris hydrogen.16. (canceled)18. The compound of claim 17 , wherein Y is —NH— claim 17 , —N(alkyl)- claim 17 , —O— claim 17 , or —CH—.1922-. (canceled)23. The compound of claim 17 , wherein Ris aryl or aralkyl.2426-. (canceled)27. The compound of claim 17 , wherein Ris hydrogen or methyl.2853-. (canceled)5564-. (canceled)65. The compound of claim 1 , wherein Ris hydroxyl or hydrogen.66. (canceled)67. The compound of claim 1 , wherein Ris hydroxyl or hydrogen.68. (canceled)69. The compound of claim 1 , wherein Ris hydrogen or methyl.7094-. (canceled)95. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable diluent or carrier.96. A kit or packaged pharmaceutical comprising a compound of and instructions for use thereof.97. A method of treating or preventing a disorder in which DOT1-mediated protein methylation plays a part claim 1 , comprising administering to a subject in need thereof a therapeutically effective amount of a compound of .98. The method of claim 97 , wherein the disorder is cancer or a neurological disorder.99. (canceled) This application claims priority to, and the benefit of, U.S. provisional application No. 61/419,591, filed Dec. 3, 2010, the content of ...

Подробнее
21-11-2013 дата публикации

7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof

Номер: US20130310334A1
Принадлежит: EPIZYME, INC.

Disclosed are compounds, pharmaceutical compositions containing the compounds, uses of the compounds and compositions as modulators of histone methyltransferases, and methods for treating diseases influenced by modulation of histone methyltransferase activity. 25-. (canceled)716-. (canceled)18. The compound of claim 17 , wherein Y is —NH— claim 17 , —N(alkyl)- claim 17 , —O— claim 17 , or —CH—.1922-. (canceled)23. The compound of claim 17 , wherein Ris aryl or aralkyl.24. The compound of claim 17 , wherein Ris substituted phenyl or substituted benzyl.26. (canceled)27. The compound of claim 17 , wherein Ris hydrogen claim 17 , or methyl.28. (canceled)29. The compound of claim 17 , wherein Ris hydrogen claim 17 , or alkyl selected from a group consisting of —CH claim 17 , —CHCH claim 17 , —CH(CH) claim 17 , —CHCH(CH)and —CHCHCH(CH).3053-. (canceled)5564-. (canceled)65. The compound of claim 1 , wherein Ris hydroxyl or hydrogen.66. (canceled)67. The compound of claim 1 , wherein Ris hydroxyl or hydrogen.68. (canceled)69. The compound of claim 1 , wherein Ris hydrogen or methyl.7079-. (canceled)8189-. (canceled)90. The compound of claim 1 , wherein Ris hydrogen or lower alkyl claim 1 , Ris hydrogen or lower alkyl claim 1 , and Ris hydrogen or lower alkyl.9196-. (canceled)98. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , hydrate claim 1 , enantiomer or stereoisomer thereof; and a pharmaceutically acceptable diluent or carrier.99. A kit or packaged pharmaceutical comprising a compound of claim 1 , and instructions for use thereof.100. A method of treating or preventing a disorder in which DOT1-mediated protein methylation plays a part claim 1 , comprising administering to a subject in need thereof a therapeutically effective amount of a compound of .101. The method of claim 100 , wherein the disorder is cancer or a neurological disorder.102. (canceled) This application claims priority to, and the benefit of ...

Подробнее
21-11-2013 дата публикации

METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES

Номер: US20130310336A1
Принадлежит:

A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. 2. The method of claim 1 , wherein Rand Rare independently H; phosphate; monophosphate; diphosphate; triphosphate; or a stabilized phosphate prodrug.3. The method of claim 1 , wherein Rand Rare each hydrogen.4. The method of claim 1 , wherein X is O.5. The method of claim 1 , wherein Ris methyl.6. The method of claim 1 , wherein Base is a purine or pyrimidine base selected from the group consisting of adenine claim 1 , N-alkylpurine claim 1 , N-acylpurine claim 1 , N-benzylpurine claim 1 , N-halopurine claim 1 , N-vinylpurine claim 1 , N-acetylenic purine claim 1 , N-acyl purine claim 1 , N-hydroxyalkyl purine claim 1 , N-thioalkyl purine claim 1 , N-alkylpurine claim 1 , N-alkyl-6-thiopurine claim 1 , thymine claim 1 , cytosine claim 1 , 5-fluorocytosine claim 1 , 5-methylcytosine claim 1 , 6-azapyrimidine claim 1 , 6-azacytosine claim 1 , 2- and/or 4-mercaptopyrimidine claim 1 , uracil claim 1 , 5-halouracil claim 1 , 5-fluorouracil claim 1 , C-alkylpyrimidine claim 1 , C-benzylpyrimidine claim 1 , C-halopyrimidine claim 1 , C-vinylpyrimidine claim 1 , C-acetylenic pyrimidine claim 1 , C-acyl pyrimidine claim 1 , C-hydroxyalkyl purine claim 1 , C-amidopyrimidine claim 1 , C-cyanopyrimidine claim 1 , C-nitropyrimidine claim 1 , C-aminopyrimidine claim 1 , N-alkylpurine claim 1 , N-alkyl-6-thiopurine claim 1 , 5-azacytidinyl claim 1 , 5-azauracilyl claim 1 , triazolopyridinyl claim 1 , imidazolopyridinyl claim 1 , pyrrolopyrimidinyl claim 1 , pyrazolopyrimidinyl claim 1 , guanine claim 1 , hypoxanthine claim 1 , 2 claim 1 ,6-diaminopurine claim 1 , and 6-chloropurine.7. The method of claim 1 , wherein Base is a purine or pyrimidine base selected from the group consisting of adenine claim ...

Подробнее
21-11-2013 дата публикации

NUCLEOSIDE PHOSPHORAMIDATES

Номер: US20130310551A1
Принадлежит:

Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. 170.-. (canceled)73. The compound according to claim 71 , wherein the compound is crystalline. This application is a continuation-in-part of U.S. patent application Ser. No. 12/783,680 filed on May 20, 2010, which claims priority to U.S. 61/179,923, filed May 20, 2009 and U.S. 61/319,513, filed on Mar. 31, 2010. Priority is claimed to U.S. 61/319,513, filed on Mar. 31, 2010 and U.S. 61/319,548, filed Mar. 31, 2010.Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.Hepatitis C virus (HCV) infection is a major health problem that leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals, estimated to be 2-15% of the world's population. There are an estimated 4.5 million infected people in the United States alone, according to the U.S. Center for Disease Control. According to the World Health Organization, there are more than 200 million infected individuals worldwide, with at least 3 to 4 million people being infected each year. Once infected, about 20% of people clear the virus, but the rest can harbor HCV the rest of their lives. Ten to twenty percent of chronically infected individuals eventually develop liver-destroying cirrhosis or cancer. The viral disease is transmitted parenterally by contaminated blood and blood products, contaminated needles, or sexually and vertically from infected mothers or carrier mothers to their ...

Подробнее
28-11-2013 дата публикации

METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS

Номер: US20130315862A1
Принадлежит:

A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. 130-. (canceled)31. A method for the treatment of a hepatitis C virus infection in a host , comprising administering to said host an anti-virally effective amount of a β-D-2′-methyl nucleoside or a phosphate thereof , or a pharmaceutically acceptable salt or ester thereof.32. The method of claim 31 , wherein an anti-virally effective amount of a β-D-2′-methyl nucleoside or a phosphate thereof claim 31 , or a pharmaceutically acceptable ester thereof is administered.33. The method of claim 32 , wherein the nucleoside is a pyrimidine nucleoside.34. The method of claim 33 , wherein the J3-D-2′-methylpyrimidine nucleoside is administered in combination or alternation with a second anti-hepatitis C agent.35. The method of claim 34 , wherein the second anti-hepatitis C agent is an interferon.36. The method of claim 34 , wherein the second anti-hepatitis C agent is ribavirin.37. The method of claim 34 , wherein the second anti-hepatitis C agent is an interferon claim 34 , ribavirin or a combination thereof.38. The method of claim 31 , wherein the nucleoside is a pyrimidine nucleoside.39. The method of claim 38 , wherein the β-D-2′-methylpyrimidine nucleoside is administered in combination or alternation with a second anti-hepatitis C agent.40. The method of claim 39 , wherein the second anti-hepatitis C agent is an interferon.41. The method of claim 39 , wherein the second anti-hepatitis C agent is ribavirin.42. The method of claim 39 , wherein the second anti-hepatitis C agent is an interferon claim 39 , ribavirin or a combination thereof.43. The method of claim 31 , wherein the β-D-2′-methyl nucleoside or a phosphate thereof claim 31 , or a pharmaceutically acceptable salt or ester thereof is in a tablet or capsule.44. ...

Подробнее
28-11-2013 дата публикации

Methods and compositions for treating flaviviridae infections

Номер: US20130315863A1

A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Подробнее
28-11-2013 дата публикации

MACROCYCLIC NUCLEOSIDE PHOSPHORAMIDATE DERIVATIVES

Номер: US20130315864A1
Принадлежит: Enanta Pharmaceuticals, Inc.

The present invention provides nucleoside phosphoramidate compounds of Formula I, 2. The compound of claim 1 , wherein:{'sup': '1', 'Ris hydrogen;'}{'sup': '2a', 'sub': '2', 'Ris methyl or —CHF;'}{'sup': '2b', 'Ris —OH or halogen;'}{'sup': 3', '4', '5a', '5b, 'R, R, Rand Rare each hydrogen;'}{'sup': '6', 'Ris aryl;'}{'sup': '7', 'Ris hydrogen;'}{'sup': 8a', '8b, 'sub': 1', '8, 'one of Rand Ris hydrogen and the other is normal or branched C-C-alkyl;'}X is O;{'sub': 4', '10', '4', '10', '2', 'n', '2', 'm, 'W is optionally substituted C-C-alkylene, optionally substituted C-C-alkenylene, or —(CH)—Y—(CH)—, where Y is O, S, NH or NMe and n and m are each independently 2 to 6; and'}M is O, NH, —OC(O)NH—, or C(O)NH.9. A pharmaceutical composition comprising a compound according to and a pharmaceutically acceptable carrier or excipient.10. A method of treating a viral infection in a subject claim 9 , comprising administering to the subject an inhibitory amount of a pharmaceutical composition according to .11. The method according to claim 10 , wherein the viral infection is hepatitis C virus.12. A method of inhibiting the replication of hepatitis C virus claim 8 , the method comprising supplying a hepatitis C viral NS3 protease inhibitory amount of the pharmaceutical composition of .13. The method of claim 11 , further comprising administering concurrently an additional anti-hepatitis C virus agent.14. The method of claim 13 , wherein said additional anti-hepatitis C virus agent is selected from the group consisting of a-interferon claim 13 , β-interferon claim 13 , ribavarin claim 13 , and adamantine.15. The method of claim 13 , wherein said additional anti-hepatitis C virus agent is an inhibitor of hepatitis C virus helicase claim 13 , polymerase claim 13 , metalloprotease claim 13 , or IRES.16. The pharmaceutical composition of claim 9 , further comprising another anti-HCV agent.17. The pharmaceutical composition of claim 9 , further comprising an agent selected from ...

Подробнее
28-11-2013 дата публикации

3',5'-CYCLIC PHOSPHATE PRODRUGS FOR HCV INFECTION

Номер: US20130315867A1
Принадлежит:

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. 2. (canceled)3. (canceled)4. The compound of claim 1 , wherein each L is independently C-Calkylene or C-Csubstituted alkylene.520-. (canceled)21. The compound of any of claim 1 , wherein:{'sub': 3', '2', 'n', '2', 'n', '3, 'each B is independently CR(CR)OC(O)CR(B—)NRC(O)O(CR)CR;'}{'sub': 2', 'n, 'where B— denotes the attachment position to the toluenyl group, Ar, L, or —(CR)—; and'}each n is independently an integer selected over the range of 0 to 10.22. The compound of claim 1 , wherein each E is independently C-Calkyl claim 1 , C-Csubstituted alkyl claim 1 , C-Caryl claim 1 , or C-Cheteroaryl.23. The compound of claim 1 , wherein each Ar is independently C-Carylene or C-Cheteroarylene.24. The compound of claim 1 , wherein each R is independently hydrogen claim 1 , C-Calkyl claim 1 , C-Csubstituted alkyl claim 1 , C-Caryl claim 1 , or C-Cheteroaryl.25. The compound of claim 1 , wherein each Ris independently a 3-20 membered carbocyclic or heterocyclic ring.2628-. (canceled)29. The compound of wherein Y is fluoro.30. The compound of wherein Y is acetoxyl.31. The compound of wherein Y is hydroxyl.32. (canceled)33. (canceled)35. The compound of claim 34 , wherein each Z is independently -LOC(O)LC(O)O(L)CRor -LOC(O)LNRC(O)O(L)CR.36. (canceled)37. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable excipient claim 1 , carrier or diluent.38. The pharmaceutical composition of claim 37 , wherein the composition is an oral formulation.39. A method for the treatment of a host infected with a hepatitis C virus claim 1 , comprising the administration of an effective treatment amount of a compound or composition of .40. The method of claim ...

Подробнее
28-11-2013 дата публикации

D-AMINO ACID COMPOUNDS FOR LIVER DISEASE

Номер: US20130315868A1
Принадлежит:

Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. 2. The compound of wherein each Ris independently alkyl claim 1 , cycloalkyl claim 1 , heterocyclylalkyl claim 1 , aryl claim 1 , heteroaryl claim 1 , arylalkyl claim 1 , heteroarylalkyl claim 1 , alkylcarbonylthioalkyl claim 1 , alkoxycarbonylalkyl claim 1 , arylalkoxycarbonylalkyl claim 1 , alkylcarbonylalkoxy(arylalkyl) claim 1 , (alkoxycarbonyl)(alkoxycarbonylamino)alkyl claim 1 , cycloalkylcarbonylalkoxyl claim 1 , alkoxycarbonylaminoalkylcarbonylthioalkyl claim 1 , hydroxylalkylcarbonylthioalkyl claim 1 , aminoalkylcarbonylalkoxycarbonylthioalkyl claim 1 , or hydantoinylalkyl.4. The compound of wherein Rand Rare H.510-. (canceled)11. The compound of wherein W is O claim 1 , and Ris Cl claim 1 , F or OH.12. (canceled)15. The compound of wherein Ris alkylamino.18. The Rcompound of .19. The Scompound of .20. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable excipient claim 1 , carrier or diluent.21. The pharmaceutical composition of claim 20 , wherein the composition is an oral formulation.22. A method for the treatment of a host infected with a hepatitis C virus claim 1 , comprising the administration of an effective treatment amount of a compound of .23. The method of claim 22 , wherein the host is a human.24. The method of claim 22 , wherein the administration directs a substantial amount of the compound claim 22 , or pharmaceutically acceptable salt or stereoisomer thereof claim 22 , to a liver of the host.25. The method of claim 22 , wherein the compound or composition is administered in combination or alternation with a second anti-viral agent selected from the group consisting of an interferon claim 22 , a ...

Подробнее
28-11-2013 дата публикации

ANTIVIRAL PHOSPHONATE ANALOGS

Номер: US20130316969A1
Принадлежит: Gilead Sciences, Inc.

The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. 2. The conjugate of wherein C-Csubstituted alkyl claim 1 , C-Csubstituted alkenyl claim 1 , C-Csubstituted alkynyl claim 1 , C-Csubstituted aryl claim 1 , and C-Csubstituted heterocycle are independently substituted with one or more substituents selected from F claim 1 , Cl claim 1 , Br claim 1 , I claim 1 , OH claim 1 , —NH claim 1 , —NH claim 1 , —NHR claim 1 , —NR claim 1 , —NR claim 1 , C-Calkylhalide claim 1 , carboxylate claim 1 , sulfate claim 1 , sulfamate claim 1 , sulfonate claim 1 , 5-7 membered ring sultam claim 1 , C-Calkylsulfonate claim 1 , C-Calkylamino claim 1 , 4-dialkylaminopyridinium claim 1 , C-Calkylhydroxyl claim 1 , C-Calkylthiol claim 1 , —SOR claim 1 , —SOAr claim 1 , —SOAr claim 1 , —SAr claim 1 , —SONR claim 1 , —SOR claim 1 , —COR claim 1 , —C(═O)NR claim 1 , 5-7 membered ring lactam claim 1 , 5-7 membered ring lactone claim 1 , —CN claim 1 , —N claim 1 , —NO claim 1 , C-Calkoxy claim 1 , C-Ctrifluoroalkyl claim 1 , C-Calkyl claim 1 , C-Ccarbocycle claim 1 , C-Caryl claim 1 , C-Cheterocycle claim 1 , polyethyleneoxy claim 1 , phosphonate claim 1 , phosphate claim 1 , and a prodrug moiety.3. The conjugate of wherein protecting group is selected from a carboxyl ester claim 1 , a carboxamide claim 1 , an aryl ether claim 1 , an alkyl ether claim 1 , a trialkylsilyl ether claim 1 , a sulfonic acid ester claim 1 , a carbonate claim 1 , and a carbamate.5. The conjugate of wherein X is O and each Ris H.14. The conjugate of wherein Z is H.15. The conjugate of wherein B is adenine.18. The conjugate of wherein Yis O.19. The conjugate of wherein Yis N(CH).21. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a conjugate as described in ...

Подробнее
28-11-2013 дата публикации

Nucleotide analogue, method of synthesis of nucleotide analogue, use of nucleotide analogue, antiviral pro-nucleotide, pharmaceutical composition

Номер: US20130316970A1

The object of the invention are nucleotide analogues, antiviral pro-nucleotides, a use of nucleotide analogues and pharmaceutical composition, a phosphorylating agent for synthesis of nucleotide analogue, and a method of synthesis of nucleotide analogue. More precisely, the invention applies to the new group of nucleotide analogues and their use in partial or complete inhibition of human immunodeficiency virus (HIV).

Подробнее
28-11-2013 дата публикации

CARBOXY X RHODAMINE ANALOGS

Номер: US20130317207A1
Принадлежит: PROMEGA CORPORATION

The present invention provides novel fluorescent dyes and kits containing the same, which are useful for labeling a wide variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis and/or treatment of disease conditions. 24.-. (canceled)5. A compound according to wherein at least one of R claim 8 , Ror Ris H.67.-. (canceled)9. A compound according to wherein X is CH.1011.-. (canceled)12. A compound according to wherein Rand Rform a 5-7 membered carbocyclic ring.1315.-. (canceled)16. A compound according to wherein Ris H claim 8 , Cl or OMe.17. A compound according to wherein Rand Rform a 5-7 membered carbocyclic ring.18. (canceled)19. A compound according to wherein at least one of R claim 8 , R claim 8 , Rand Ris H.2024.-. (canceled)25. A compound according to wherein Ris H claim 8 , Cl or OMe.26. A compound according to wherein Ris Calkyl.27. A compound according to wherein Ris methyl or ethyl.28227. A compound according to any one of claims - wherein Ris Calkyl.29. A compound according to wherein Ris methyl or ethyl.30. A compound according to wherein Ris part of a heterocycle.31. (canceled)32. A compound according to wherein Ris part of a heterocycle.3344.-. (canceled)45. A compound according to wherein Ris H.46. A compound according to wherein Ris H.47. A compound according to wherein Ris H or halogen.48. A compound according to wherein Ris H or halogen.49. A compound according to wherein Ris H claim 8 , F claim 8 , Cl COH or SOH.50. A compound according to wherein one of Rand Ris -L-R claim 8 , -L-COH or -L-Cand the other is H claim 8 , Cl claim 8 , or F.51. A compound according to wherein L is —CO— claim 8 , —SCHCO— claim 8 , or —SO—.52. A compound according to is a self-immolative linker.54. A compound according to wherein Cis NHCHCH(OCHCH)(CH)Cl claim 8 , wherein n is 2-6.55. A compound ...

Подробнее
05-12-2013 дата публикации

Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis b

Номер: US20130324491A1

This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

Подробнее
05-12-2013 дата публикации

URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF

Номер: US20130324495A1
Принадлежит:

The invention provides particular uridine di- and tri-phosphate derivatives, and pharmaceutical compositions thereof. These compounds are useful for treatment of diseases, disorders and conditions modulated by P2Y6 receptors, and particularly for lowering intraocular pressure and thereby treating ocular hypertension and/or glaucoma. 2. The compound of claim 1 , wherein R is —O—(C-C)alkyl or —S—(C-C)alkyl.3. The compound of claim 1 , wherein R is —O—(C-C)alkyl or —S—(C-C)alkyl.4. The compound of claim 1 , wherein n is 0 claim 1 , and at least one of Zand Zis BH; or n is 1 claim 1 , and at least one of Zto Zis BH.5. The compound of claim 4 , wherein n is 0 claim 4 , and (i) Zis BH claim 4 , and Zis O; (ii) Zis BH claim 4 , and Zis O; or (iii) Zand Zare BH.6. The compound of claim 4 , wherein n is 1 claim 4 , and (i) Zis BH claim 4 , and Zand Zare O; (ii) Zis BH claim 4 , and Zand Zare O; (iii) Zis BH claim 4 , and Zand Zare O; (iv) Zand Zare BH claim 4 , and Zis O; (v) Zand Zare BH claim 4 , and Zis O; (vi) Zand Zare BH claim 4 , and Zis O; or (vii) Zto Zare BH.7. The compound of claim 1 , wherein R is —O—(C-C)alkyl claim 1 , n is 0 claim 1 , and (i) Zis BH claim 1 , and Zis O; (ii) Zis O claim 1 , and Zis BH; or (iii) Zand Zare BH.8. The compound of claim 7 , wherein R is —OCH claim 7 , Y each is —OH claim 7 , n is 0 claim 7 , Zis BH claim 7 , and Zis O claim 7 , herein identified compound 13.9. The compound of claim 8 , characterized by being the isomer with a retention time (R) of 8.97 min when separated from a mixture of diastereoisomers using a semi-preparative reverse-phase Gemini 5μ column (C-18 110 A claim 8 , 250×10 mm claim 8 , 5 micron) claim 8 , and isocratic elution [100 mM triethylammonium acetate claim 8 , pH 7: CHCN claim 8 , 94:6] with flow rate of 5 ml/min claim 8 , herein identified compound 13A.10. The compound of claim 7 , wherein R is —OCH claim 7 , Y each is —OH claim 7 , n is 1 claim 7 , Zis BH claim 7 , and Zand Zis O claim 7 , herein ...

Подробнее
12-12-2013 дата публикации

NOVEL ANTIBACTERIAL COMPOUNDS

Номер: US20130331351A1
Принадлежит:

The present invention relates to compounds of formula (I): wherein Rj, R2, R3, R4, Xi, X2, X3 and Z are as defined in claim . The compounds are useful in the prevention and/or treatment of bacterial infections. 3: The compound of claim 2 , wherein Xis —O— or —NH—.5: The compound of claim 1 , wherein Xis —CH—.6: The compound of claim 1 , wherein Ris NHor OH.7: The compound of claim 1 , wherein Ris H.8: The compound of claim 1 , wherein Ris H.9: The compound of any claim 1 , wherein Ris H.10: The compound of claim 1 , wherein Ris H.11: The compound of wherein the compound is 5′-amino-5′-deoxyadenosin-8-yl-thio-N-[(5′-amino-5′-deoxyadenosine)methyl]acetamide; 8-[3-N-(5′-deoxyadenosyl)aminoprop-1-ynyl]adenosine; 8-[3-(5′-deoxyadenosyl)methoxyprop-1-ynyl]adenosine claim 1 , or any combination thereof.12: A pharmaceutical composition comprising the compound of claim 1 , in admixture with one or more pharmaceutically acceptable excipients.13: The compound of claim 1 , wherein the compound is suitable for prevention claim 1 , treatment claim 1 , or both prevention and treatment of a bacterial infection.16: A chemical probe comprising the compound of claim 1 , coupled to a detectable label.17. (canceled)18: A method for screening a molecule inhibiting NAD kinase claim 1 , the method comprising:{'claim-ref': {'@idref': 'CLM-00016', 'claim 16'}, 'contacting NAD kinase with the chemical probe of with a molecule to be screened;'}determining a quantity of chemical probe bound or unbounded to the NAD kinase; anddeducing from the quantity if the molecule is an inhibitor of the NAD kinase.19: A method of treating a bacterial infection claim 1 , the method comprising administering the compound of to a subject in need thereof. The present invention relates to compounds for use in the prevention and/or treatment of bacterial infections, pharmaceutical compositions comprising them, and processes for the preparation thereof.The search for new antibacterial compounds has become ...

Подробнее
19-12-2013 дата публикации

Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids

Номер: US20130337581A1
Принадлежит: UNIVERSITY OF IDAHO

Embodiments are disclosed herein that involve C5-functionalized nucleic acids, which can be used for detecting a target in a nucleic acid. Particular embodiments disclose methods for making these compounds, wherein the compounds can be formed by coupling of an intermediate with a linker. Certain embodiments disclose the use of these compounds for detecting single nucleotide polymorphisms, and for increasing the thermal affinity of nucleic acid complements as compared to unmodified nucleic acid complements. In addition, the disclosed compounds can decrease enzymatic degradation of nucleic acids.

Подробнее
19-12-2013 дата публикации

SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES

Номер: US20130338094A1
Принадлежит: Millennium Pharmaceuticals, Inc.

The present disclosure relates to compounds of formula (I-A) using the compounds 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , characterized by one or more of the following features:(a) X is —O—;{'sub': '2', '(b) Y is —O— or —CH—;'}{'sup': '3a', '(c) Ris —OH;'}{'sup': 3b', '3, 'sub': '1-4', '(d) Rand Rare each independently hydrogen or Caliphatic;'}{'sup': 3', '5, '(e) Ris hydrogen, fluoro, or —OR;'}{'sup': 5', '5′, '(f) Rand Rare each hydrogen;'}{'sup': '4', '(g) each Ris hydrogen;'}{'sup': '2', '(h) each Ris hydrogen;'}{'sup': 'h', '(i) Ris hydrogen;'}{'sup': 'j', '(j) Ris hydrogen; and'}{'sup': 'k', 'sub': '1-4', '(k) Ris hydrogen, halo, or Caliphatic.'}4. The compound of claim 3 , or a pharmaceutically acceptable salt thereof claim 3 , characterized by one or more of the features (a) through (f):{'sup': '3a', 'sub': 1-4', '1-4, '(a) Ris hydrogen, hydroxy, methoxy, Caliphatic, Cfluoroaliphatic, or fluoro;'}{'sup': '3', '(b) Ris hydrogen;'}{'sup': '3', '(c) Ris hydrogen or hydroxy;'}{'sup': '3d', '(d) Ris hydrogen;'}{'sup': '4', '(e) each Ris hydrogen; and'}{'sup': '5', '(f) Ris hydrogen.'}9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof claim 8 , wherein Ring B is a phenyl ring substituted with 0-2 substituents independently selected from the group halo claim 8 , —OH claim 8 , —O(Calkyl) claim 8 , —CN claim 8 , —N(R) claim 8 , —C(O)(Calkyl) claim 8 , —COH claim 8 , —CO(Calkyl) claim 8 , —C(O)N H claim 8 , —C(O)NH(Calkyl) claim 8 , —Caliphatic claim 8 , —Cfluoroaliphatic claim 8 , —O(Cfluoroaliphatic) claim 8 , optionally substituted aryl claim 8 , and optionally substituted heteroaryl.10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein:{'sup': 1', '12a', '12b', '12a', '12b', '12a', '12d, 'sub': '1-10', 'Ris Caliphatic, —Z—R, —Z—R, -L-Z—R, -L-Z—R, -L-Ror -L-R;'}{'sup': 13', '3, 'L is —C(R)═C(R)— or —C≡C—; and'}{'sup': 12d', '15', '15', '16', '14', '14', '16, ...

Подробнее
02-01-2014 дата публикации

NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Номер: US20140005136A1
Принадлежит: Ardea Biosciences, Inc.

Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. 2. The compound of claim 1 , wherein:X is N.3. The compound of claim 1 , wherein:W is S or O.5. The compound of claim 4 , wherein:{'img': {'@id': 'CUSTOM-CHARACTER-00008', '@he': '2.12mm', '@wi': '4.57mm', '@file': 'US20140005136A1-20140102-P00001.TIF', '@alt': 'custom-character', '@img-content': 'character', '@img-format': 'tif'}, 'represents a carbon-carbon double bond; and'}{'sup': 'P', 'Ris cyclopropyl.'}6. The compound of claim 1 , wherein:X is N;W is S; and{'sup': '1', 'sub': 3', '2', '2, 'Ris Cl, Br, I, optionally substituted methyl, CF, CHFor CHF.'}7. The compound of claim 1 , wherein:{'sup': 3', '3′, 'Rand R are not H.'}8. The compound of claim 1 , wherein:{'sup': 3', '3′, 'Rand R are H.'}9. The compound of claim 1 , wherein:{'sup': 3', '3′, 'Rand R together with the carbon to which they are attached form a 4-, 5-, or 6-membered ring, optionally containing 1 or 2 heteroatoms selected from N, S and O.'}10. The compound of claim 1 , wherein:{'sup': 3', '3′, 'Rand R together with the carbon to which they are attached form a 4-, 5-, or 6-membered ring.'}12. The compound of claim 11 , wherein:{'sup': '1a', 'Ris at least one amino acid.'}13. The compound of claim 11 , wherein:{'sup': '1a', 'Ris a peptide.'}14. The compound of claim 11 , wherein:{'sup': '1a', 'Ris a lipid.'}15. The compound of claim 11 , wherein:{'sup': '1a', 'Ris a phospholipid.'}16. The compound of claim 11 , wherein:{'sup': '1a', 'Ris a glycoside.'}17. The compound of claim 11 , wherein:{'sup': '1a', 'Ris a nucleoside.'}18. The compound of claim 11 , wherein:{'sup': '1a', 'Ris a nucleotide.'}19. The compound of claim 11 , wherein:{'sup': '1a', 'Ris an oligonucleotide.'}20. The compound of claim 11 , wherein:{'sup': ...

Подробнее
02-01-2014 дата публикации

Ribofuranosyl Purine Compounds, Methods for Preparing the Same and Use Thereof

Номер: US20140005138A1
Принадлежит:

The present invention relates to the compounds of the formulae (I) and (I-1) and the process for preparing the same, uses of the compounds for the treatment of diseases associated with platelet aggregation and in the manufacture of a medicament for the treatment of diseases associated with platelet aggregation, and relates to a pharmaceutical composition and a pharmaceutical formulation containing the compounds, wherein the definitions of R, R, Rand Rin the formulae are the same as those in the description. 2. The compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein Rrepresents an unsubstituted or R-substituted C-Calkyl claim 1 , wherein Rrepresents halogen claim 1 , C-Calkyl claim 1 , C-Calkoxyl claim 1 , halogenated C-Calkyl claim 1 , halogenated C-Calkoxyl claim 1 , hydroxyl claim 1 , hydroxyl C-Calkyl claim 1 , carboxyl claim 1 , nitro claim 1 , cyano claim 1 , C-Calkylthio claim 1 , or C-Calkyl-CO—.3. The compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein Rrepresents an unsubstituted or R-substituted C-Calkyl claim 1 , an unsubstituted or R-substituted C-Ccycloalkyl claim 1 , an unsubstituted or R-substituted 5- to 6-membered heteroaryl-C-Calkyl claim 1 , an unsubstituted or R-substituted phenyl-C-Calkyl claim 1 , or an unsubstituted or R-substituted 5- to 6-membered heterocyclyl-C-Calkyl claim 1 , wherein Ris selected from the group consisting of C-Calkyl claim 1 , C-Calkoxyl claim 1 , hydroxyl claim 1 , hydroxyl C-Calkyl claim 1 , carboxyl claim 1 , nitro claim 1 , cyano claim 1 , C-Calkylthio and C-Calkyl-CO—; and Ris selected from the group consisting of halogen claim 1 , C-Calkyl claim 1 , C-Calkoxyl claim 1 , hydroxyl claim 1 , hydroxyl C-Calkyl claim 1 , carboxyl claim 1 , nitro claim 1 , cyano claim 1 , C-Calkylthio claim 1 , and C-Calkyl-CO—.4. The compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein Rrepresents C-Calkyl; Rrepresents C-Calkyl claim 1 , ...

Подробнее
09-01-2014 дата публикации

1,2,3-Triazolyl Purine Derivatives

Номер: US20140011763A1
Автор: Mahesh K. Lakshman

The present invention relates to novel 1,2,3-triazolyl purine derivatives. The invention also relates to using the derivatives to treat cancer and various viral infections. An example of a 1,2,3-triazolyl purine derivative of the invention is

Подробнее
16-01-2014 дата публикации

METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS

Номер: US20140018314A1
Принадлежит: INOTEK PHARMACEUTICALS CORPORATION

Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). 116-. (canceled)18. The method of claim 17 , wherein about 20 μg to about 700 μg of a compound of Formula II or a pharmaceutically acceptable salt thereof claim 17 , is administered to an affected eye of the human subject.19. The method of claim 17 , wherein the compound is administered from 1 to 4 times daily.20. The method of claim 18 , wherein the compound is administered from 1 to 2 times daily.21. The method of claim 17 , wherein about 350 μg of a compound of Formula II claim 17 , or a pharmaceutically acceptable salt thereof claim 17 , is administered from 1 to 2 times daily.23. The method of claim 22 , wherein about 0.05 mg/ml to about 7.0 mg/ml of a compound of Formula II claim 22 , or a pharmaceutically acceptable salt thereof claim 22 , is administered to an affected eye of the human subject.24. The method of claim 22 , wherein about 20 μg to 700 μg of a compound of Formula II claim 22 , or a pharmaceutically acceptable salt thereof claim 22 , is administered to an affected eye of the human subject.25. The method of claim 23 , wherein the compound is administered from 1 to 4 times daily.26. The method of claim 24 , wherein the compound is administered from 1 to 2 times daily.27. The method of claim 22 , wherein about 350 μg of a compound of Formula II claim 22 , or a pharmaceutically acceptable salt thereof claim 22 , is administered from 1 to 2 times daily.32. The method of or claim 22 , wherein Ris selected from —(CO)CH(CH) claim 22 ...

Подробнее
23-01-2014 дата публикации

FLUORINATED PYRIMIDINE ANALOGS AND METHODS OF USE THEREOF

Номер: US20140024612A1
Принадлежит: OncoGenex Pharmaceuticals, Inc.

Fluorinated pyrimidine analog compounds, compositions that include the fluorinated pyrimidine analog compounds, methods for making the fluorinated pyrimidine analog compounds, and methods for inhibiting DNA methyltransferase, treating solid tumors, and treating hematologic cancers by administering the fluorinated pyrimidine analog compounds. 1. 2′ ,2′-Difluoro-5-azadeoxycytidine , its anomers , and pharmaceutically acceptable salts thereof.2. A pharmaceutical composition claim 1 , comprising the compound of and a pharmaceutically acceptable carrier.3. A method for inhibiting DNA methyltransferase in a subject claim 1 , comprising administering a therapeutically effective amount of a compound of to the subject.4. A method for treating a cancer treatable by inhibiting DNA methyltransferase claim 1 , comprising administering a therapeutically effective amount of a compound of to a subject in need thereof.5. A method of treating a solid tumor carcinoma claim 1 , comprising administering a therapeutically effective amount of a compound of to a subject in need thereof.6. The method of claim 5 , wherein the solid tumor carcinoma is selected from the group consisting of breast claim 5 , non-small cell lung claim 5 , colon claim 5 , renal claim 5 , ovarian claim 5 , and colorectal carcinomas.7. A method of treating a hematologic malignancy claim 1 , comprising administering a therapeutically effective amount of a compound of to a subject in need thereof.8. The method of claim 7 , wherein the hematologic malignancy is a leukemia.9. The method of claim 8 , wherein the leukemia is resistant to decitabine (5-azadeoxycytidine).10. The method of claim 3 , wherein the subject is a human.11. 2′ claim 3 ,2′-Difluoro-5 claim 3 ,6-dihydro-5-azadeoxycytidine claim 3 , its anomers claim 3 , and pharmaceutically acceptable salts thereof.12. A pharmaceutical composition claim 11 , comprising the compound of and a pharmaceutically acceptable carrier.13. A method of treating a solid tumor ...

Подробнее
30-01-2014 дата публикации

6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY

Номер: US20140031539A1
Принадлежит: Biocodex, Inc

The present invention relates to certain purines, which act as topoisomerase II catalytic inhibitors. These compounds are useful in combination with topoisomerase II poisons, such as anthracyclines and epipodophyllotoxins, in the treatment of proliferative conditions (e.g., cancer). These compounds are useful in the treatment of tissue damage associated with extravasation of a topoisomerase II poison, such as an anthracycline or an epipodophyllotoxin. 2104.-. (canceled) This application is related to: United Kingdom patent application 0502573.9 filed 8 Feb. 2005, the contents of which are incorporated herein by reference in their entirety.The present invention relates to topoisomerase II catalytic inhibitors, and their use in therapy. In particular, the present invention relates to certain purines (6-ether/thioether-purines) and derivatives thereof for use in combination with cytostatic agents that act as topoisomerase II poisons, such as anthracyclines and epipodophyllotoxins, in the treatment of proliferative conditions (e.g., cancer). The present invention also relates to use of these compounds in the treatment of tissue damage associated with accidental extravasation of a topoisomerase II poison, such as an anthracycline or an epipodophyllotoxin.A number of patents and publications are cited herein in order to more fully describe and disclose the invention and the state of the art to which the invention pertains. Each of these references is incorporated herein by reference in its entirety into the present disclosure, to the same extent as if each individual reference was specifically and individually indicated to be incorporated by reference.Throughout this specification, including the claims which follow, unless the context requires otherwise, the word “comprise,” and variations such as “comprises” and “comprising,” will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or ...

Подробнее